BR112014020786A2 - método para tratamento de câncer de pulmão, método para alcançar um critério de avaliação de resposta em tumores sólidos, método para aumento da sobrevivência - Google Patents

Info

Publication number

BR112014020786A2

BR112014020786A2 BR112014020786-0A BR112014020786A BR112014020786A2 BR 112014020786 A2 BR112014020786 A2 BR 112014020786A2 BR 112014020786 A BR112014020786 A BR 112014020786A BR 112014020786 A2 BR112014020786 A2 BR 112014020786A2

Authority

BR

Brazil

Prior art keywords

substituted

unsubstituted

pyrazin

tor kinase

imidazo

Prior art date

2012-02-24

Links

• Espacenet
• Global Dossier
• Discuss

• 206010028980 Neoplasm Diseases 0.000 title claims abstract description 91
• 238000000034 method Methods 0.000 title claims abstract description 83
• 230000004044 response Effects 0.000 title claims abstract description 43
• 230000004083 survival effect Effects 0.000 title claims abstract description 15
• 206010058467 Lung neoplasm malignant Diseases 0.000 title abstract description 7
• 201000005202 lung cancer Diseases 0.000 title abstract description 7
• 208000020816 lung neoplasm Diseases 0.000 title abstract description 7
• 238000011282 treatment Methods 0.000 title description 66
• 238000011156 evaluation Methods 0.000 title description 8
• 108010065917 TOR Serine-Threonine Kinases Proteins 0.000 claims abstract description 399
• 102000013530 TOR Serine-Threonine Kinases Human genes 0.000 claims abstract description 399
• 229940043355 kinase inhibitor Drugs 0.000 claims abstract description 398
• 239000003757 phosphotransferase inhibitor Substances 0.000 claims abstract description 398
• 239000005551 L01XE03 - Erlotinib Substances 0.000 claims abstract description 159
• AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 claims abstract description 159
• 229960001433 erlotinib Drugs 0.000 claims abstract description 159
• UHDGCWIWMRVCDJ-ZAKLUEHWSA-N cytidine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-ZAKLUEHWSA-N 0.000 claims abstract description 135
• 208000002154 non-small cell lung carcinoma Diseases 0.000 claims abstract description 84
• 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims abstract description 70
• UHDGCWIWMRVCDJ-UHFFFAOYSA-N 1-beta-D-Xylofuranosyl-NH-Cytosine Natural products O=C1N=C(N)C=CN1C1C(O)C(O)C(CO)O1 UHDGCWIWMRVCDJ-UHFFFAOYSA-N 0.000 claims abstract description 21
• UHDGCWIWMRVCDJ-PSQAKQOGSA-N Cytidine Natural products O=C1N=C(N)C=CN1[C@@H]1[C@@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-PSQAKQOGSA-N 0.000 claims abstract description 21
• 125000003118 aryl group Chemical group 0.000 claims description 125
• 150000001875 compounds Chemical class 0.000 claims description 115
• 125000000753 cycloalkyl group Chemical group 0.000 claims description 102
• 125000000217 alkyl group Chemical group 0.000 claims description 96
• NMUSYJAQQFHJEW-KVTDHHQDSA-N 5-azacytidine Chemical group O=C1N=C(N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NMUSYJAQQFHJEW-KVTDHHQDSA-N 0.000 claims description 83
• 229960002756 azacitidine Drugs 0.000 claims description 82
• 125000004415 heterocyclylalkyl group Chemical group 0.000 claims description 63
• 125000000623 heterocyclic group Chemical group 0.000 claims description 41
• 150000003839 salts Chemical class 0.000 claims description 36
• 239000003814 drug Substances 0.000 claims description 35
• 239000000651 prodrug Substances 0.000 claims description 28
• 229940002612 prodrug Drugs 0.000 claims description 28
• 239000012453 solvate Substances 0.000 claims description 27
• 229940079593 drug Drugs 0.000 claims description 26
• 201000010099 disease Diseases 0.000 claims description 19
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 19
• 125000003710 aryl alkyl group Chemical group 0.000 claims description 10
• 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims description 10
• 230000036961 partial effect Effects 0.000 claims description 9
• 206010061309 Neoplasm progression Diseases 0.000 claims description 7
• 230000005751 tumor progression Effects 0.000 claims description 5
• 101100113998 Mus musculus Cnbd2 gene Proteins 0.000 claims 2
• 230000000087 stabilizing effect Effects 0.000 claims 1
• 108091000080 Phosphotransferase Proteins 0.000 abstract description 12
• 102000020233 phosphotransferase Human genes 0.000 abstract description 12
• 101710088998 Response regulator inhibitor for tor operon Proteins 0.000 abstract description 4
• 239000007787 solid Substances 0.000 abstract description 4
• -1 -sec-butyl Chemical group 0.000 description 455
• HUTNOYOBQPAKIA-UHFFFAOYSA-N 1h-pyrazin-2-one Chemical compound OC1=CN=CC=N1 HUTNOYOBQPAKIA-UHFFFAOYSA-N 0.000 description 209
• 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 122
• 229940125904 compound 1 Drugs 0.000 description 109
• 125000001072 heteroaryl group Chemical group 0.000 description 78
• 125000004204 2-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C(OC([H])([H])[H])C([H])=C1[H] 0.000 description 68
• 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 65
• 239000003795 chemical substances by application Substances 0.000 description 56
• 125000004208 3-hydroxyphenyl group Chemical group [H]OC1=C([H])C([H])=C([H])C(*)=C1[H] 0.000 description 54
• 210000004027 cell Anatomy 0.000 description 52
• 239000000203 mixture Substances 0.000 description 52
• 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 34
• KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 description 33
• KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 33
• LAQJGAKLLZAETL-UHFFFAOYSA-N 2h-pyrazin-3-one Chemical compound O=C1CN=CC=N1 LAQJGAKLLZAETL-UHFFFAOYSA-N 0.000 description 32
• 125000001424 substituent group Chemical group 0.000 description 32
• 125000001305 1,2,4-triazol-3-yl group Chemical group [H]N1N=C([*])N=C1[H] 0.000 description 30
• 125000004076 pyridyl group Chemical group 0.000 description 29
• 125000003107 substituted aryl group Chemical group 0.000 description 28
• 125000004210 cyclohexylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 26
• 230000003902 lesion Effects 0.000 description 26
• 230000000694 effects Effects 0.000 description 23
• 229910052757 nitrogen Inorganic materials 0.000 description 22
• 238000009472 formulation Methods 0.000 description 21
• 230000035772 mutation Effects 0.000 description 21
• 125000004203 4-hydroxyphenyl group Chemical group [H]OC1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 20
• 102100023421 Nuclear receptor ROR-gamma Human genes 0.000 description 19
• JUJWROOIHBZHMG-UHFFFAOYSA-N UNPD92016 Natural products C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 19
• 201000011510 cancer Diseases 0.000 description 18
• UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 18
• 150000003222 pyridines Chemical class 0.000 description 18
• 238000007792 addition Methods 0.000 description 17
• 230000002265 prevention Effects 0.000 description 17
• 239000003826 tablet Substances 0.000 description 17
• 125000004093 cyano group Chemical group *C#N 0.000 description 16
• 230000009467 reduction Effects 0.000 description 16
• IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 15
• RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 15
• JFDZBHWFFUWGJE-UHFFFAOYSA-N benzonitrile Chemical compound N#CC1=CC=CC=C1 JFDZBHWFFUWGJE-UHFFFAOYSA-N 0.000 description 15
• 230000037396 body weight Effects 0.000 description 15
• 229910052736 halogen Inorganic materials 0.000 description 15
• 150000002367 halogens Chemical class 0.000 description 15
• 230000005764 inhibitory process Effects 0.000 description 15
• 102000001253 Protein Kinase Human genes 0.000 description 14
• SMWDFEZZVXVKRB-UHFFFAOYSA-N anhydrous quinoline Natural products N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 14
• 125000004429 atom Chemical group 0.000 description 14
• SIKJAQJRHWYJAI-UHFFFAOYSA-N benzopyrrole Natural products C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 14
• PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 14
• RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 14
• 150000002475 indoles Chemical class 0.000 description 14
• 229910052760 oxygen Inorganic materials 0.000 description 14
• 108060006633 protein kinase Proteins 0.000 description 14
• 150000003248 quinolines Chemical class 0.000 description 14
• 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 13
• 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 description 13
• 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 description 13
• YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 description 13
• 125000001624 naphthyl group Chemical group 0.000 description 13
• 125000004432 carbon atom Chemical group C* 0.000 description 12
• 208000037821 progressive disease Diseases 0.000 description 12
• 125000004200 2-methoxyethyl group Chemical group [H]C([H])([H])OC([H])([H])C([H])([H])* 0.000 description 11
• 241001465754 Metazoa Species 0.000 description 11
• 125000003545 alkoxy group Chemical group 0.000 description 11
• KXDAEFPNCMNJSK-UHFFFAOYSA-N benzene carboxamide Natural products NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 description 11
• PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 description 10
• NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 10
• 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 10
• 239000002775 capsule Substances 0.000 description 10
• 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 10
• 125000002887 hydroxy group Chemical group [H]O* 0.000 description 10
• 150000003254 radicals Chemical group 0.000 description 10
• 125000004343 1-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])(*)C([H])([H])[H] 0.000 description 9
• 206010061818 Disease progression Diseases 0.000 description 9
• YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical group C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 9
• 238000004458 analytical method Methods 0.000 description 9
• 230000005750 disease progression Effects 0.000 description 9
• 125000002768 hydroxyalkyl group Chemical group 0.000 description 9
• 150000003230 pyrimidines Chemical class 0.000 description 9
• 208000011581 secondary neoplasm Diseases 0.000 description 9
• 208000024891 symptom Diseases 0.000 description 9
• 230000004614 tumor growth Effects 0.000 description 9
• 239000003981 vehicle Substances 0.000 description 9
• PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 8
• 239000000090 biomarker Substances 0.000 description 8
• 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 8
• 230000003111 delayed effect Effects 0.000 description 8
• 229910052731 fluorine Inorganic materials 0.000 description 8
• 239000011737 fluorine Substances 0.000 description 8
• 239000000243 solution Substances 0.000 description 8
• 238000012360 testing method Methods 0.000 description 8
• 238000002560 therapeutic procedure Methods 0.000 description 8
• 229930192474 thiophene Natural products 0.000 description 8
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
• XAUDJQYHKZQPEU-KVQBGUIXSA-N 5-aza-2'-deoxycytidine Chemical group O=C1N=C(N)N=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 XAUDJQYHKZQPEU-KVQBGUIXSA-N 0.000 description 7
• WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 7
• 239000008280 blood Substances 0.000 description 7
• 238000011161 development Methods 0.000 description 7
• 230000018109 developmental process Effects 0.000 description 7
• 229940121647 egfr inhibitor Drugs 0.000 description 7
• 125000005842 heteroatom Chemical group 0.000 description 7
• 125000000592 heterocycloalkyl group Chemical group 0.000 description 7
• 125000001041 indolyl group Chemical group 0.000 description 7
• 230000037361 pathway Effects 0.000 description 7
• 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 7
• 125000004307 pyrazin-2-yl group Chemical group [H]C1=C([H])N=C(*)C([H])=N1 0.000 description 7
• 125000003226 pyrazolyl group Chemical group 0.000 description 7
• 125000000714 pyrimidinyl group Chemical group 0.000 description 7
• 229920006395 saturated elastomer Polymers 0.000 description 7
• 239000000725 suspension Substances 0.000 description 7
• 229940124597 therapeutic agent Drugs 0.000 description 7
• 150000003577 thiophenes Chemical class 0.000 description 7
• 125000001425 triazolyl group Chemical group 0.000 description 7
• QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
• 150000004923 Erlotinib derivatives Chemical class 0.000 description 6
• 229920002472 Starch Polymers 0.000 description 6
• 238000003556 assay Methods 0.000 description 6
• 210000004369 blood Anatomy 0.000 description 6
• 239000003153 chemical reaction reagent Substances 0.000 description 6
• KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
• 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 6
• 230000007423 decrease Effects 0.000 description 6
• 239000003085 diluting agent Substances 0.000 description 6
• ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 6
• 125000005843 halogen group Chemical group 0.000 description 6
• 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 6
• 239000003112 inhibitor Substances 0.000 description 6
• 230000000155 isotopic effect Effects 0.000 description 6
• 239000002207 metabolite Substances 0.000 description 6
• 238000002360 preparation method Methods 0.000 description 6
• 108090000623 proteins and genes Proteins 0.000 description 6
• 238000012216 screening Methods 0.000 description 6
• QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical class C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 6
• 235000019698 starch Nutrition 0.000 description 6
• 239000000126 substance Substances 0.000 description 6
• 238000001356 surgical procedure Methods 0.000 description 6
• 230000001225 therapeutic effect Effects 0.000 description 6
• 102000009308 Mechanistic Target of Rapamycin Complex 2 Human genes 0.000 description 5
• 108010034057 Mechanistic Target of Rapamycin Complex 2 Proteins 0.000 description 5
• XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 5
• 239000002253 acid Substances 0.000 description 5
• 238000001574 biopsy Methods 0.000 description 5
• 230000022131 cell cycle Effects 0.000 description 5
• 125000004122 cyclic group Chemical group 0.000 description 5
• 125000004851 cyclopentylmethyl group Chemical group C1(CCCC1)C* 0.000 description 5
• 206010012601 diabetes mellitus Diseases 0.000 description 5
• 150000002148 esters Chemical class 0.000 description 5
• 125000001188 haloalkyl group Chemical group 0.000 description 5
• 229910052739 hydrogen Inorganic materials 0.000 description 5
• HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 5
• 239000008194 pharmaceutical composition Substances 0.000 description 5
• 125000002071 phenylalkoxy group Chemical group 0.000 description 5
• 102000004169 proteins and genes Human genes 0.000 description 5
• 239000008107 starch Substances 0.000 description 5
• 229910052717 sulfur Inorganic materials 0.000 description 5
• 230000002195 synergetic effect Effects 0.000 description 5
• 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 4
• QEVNUSASORPKFA-UHFFFAOYSA-N 9-benzyl-2-methylpurine-6-carboxamide Chemical compound C12=NC(C)=NC(C(N)=O)=C2N=CN1CC1=CC=CC=C1 QEVNUSASORPKFA-UHFFFAOYSA-N 0.000 description 4
• DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 4
• 239000005711 Benzoic acid Substances 0.000 description 4
• 229920002134 Carboxymethyl cellulose Polymers 0.000 description 4
• FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 4
• ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 4
• OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 4
• VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
• GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
• 229930195725 Mannitol Natural products 0.000 description 4
• 102000008135 Mechanistic Target of Rapamycin Complex 1 Human genes 0.000 description 4
• 108010035196 Mechanistic Target of Rapamycin Complex 1 Proteins 0.000 description 4
• 241000699670 Mus sp. Species 0.000 description 4
• 108091007960 PI3Ks Proteins 0.000 description 4
• 102000038030 PI3Ks Human genes 0.000 description 4
• XYFCBTPGUUZFHI-UHFFFAOYSA-N Phosphine Chemical compound P XYFCBTPGUUZFHI-UHFFFAOYSA-N 0.000 description 4
• FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
• QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
• 125000003342 alkenyl group Chemical group 0.000 description 4
• 230000001028 anti-proliverative effect Effects 0.000 description 4
• 239000011230 binding agent Substances 0.000 description 4
• 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 4
• 235000010948 carboxy methyl cellulose Nutrition 0.000 description 4
• 235000010980 cellulose Nutrition 0.000 description 4
• 229920002678 cellulose Polymers 0.000 description 4
• 238000002512 chemotherapy Methods 0.000 description 4
• 238000011284 combination treatment Methods 0.000 description 4
• 230000007748 combinatorial effect Effects 0.000 description 4
• 239000013078 crystal Substances 0.000 description 4
• PNZXMIKHJXIPEK-UHFFFAOYSA-N cyclohexanecarboxamide Chemical compound NC(=O)C1CCCCC1 PNZXMIKHJXIPEK-UHFFFAOYSA-N 0.000 description 4
• 230000006378 damage Effects 0.000 description 4
• 230000003247 decreasing effect Effects 0.000 description 4
• 230000008034 disappearance Effects 0.000 description 4
• 125000002883 imidazolyl group Chemical group 0.000 description 4
• 230000002401 inhibitory effect Effects 0.000 description 4
• 239000008101 lactose Substances 0.000 description 4
• 229960001375 lactose Drugs 0.000 description 4
• 239000000314 lubricant Substances 0.000 description 4
• 239000000594 mannitol Substances 0.000 description 4
• 235000010355 mannitol Nutrition 0.000 description 4
• 229920000609 methyl cellulose Polymers 0.000 description 4
• 235000010981 methylcellulose Nutrition 0.000 description 4
• 239000001923 methylcellulose Substances 0.000 description 4
• 229920001223 polyethylene glycol Polymers 0.000 description 4
• 238000001959 radiotherapy Methods 0.000 description 4
• ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 4
• 230000011664 signaling Effects 0.000 description 4
• 229960002930 sirolimus Drugs 0.000 description 4
• 235000000346 sugar Nutrition 0.000 description 4
• 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 3
• 125000004198 2-fluorophenyl group Chemical group [H]C1=C([H])C(F)=C(*)C([H])=C1[H] 0.000 description 3
• 125000006497 3-methoxybenzyl group Chemical group [H]C1=C([H])C(=C([H])C(OC([H])([H])[H])=C1[H])C([H])([H])* 0.000 description 3
• 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 description 3
• HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 3
• GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 3
• WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 3
• 206010007270 Carcinoid syndrome Diseases 0.000 description 3
• ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 3
• KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
• WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
• PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
• AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 3
• 208000002193 Pain Diseases 0.000 description 3
• 239000002202 Polyethylene glycol Substances 0.000 description 3
• 229930006000 Sucrose Natural products 0.000 description 3
• CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
• 208000026911 Tuberous sclerosis complex Diseases 0.000 description 3
• KPCZJLGGXRGYIE-UHFFFAOYSA-N [C]1=CC=CN=C1 Chemical group [C]1=CC=CN=C1 KPCZJLGGXRGYIE-UHFFFAOYSA-N 0.000 description 3
• 125000004442 acylamino group Chemical group 0.000 description 3
• 230000000996 additive effect Effects 0.000 description 3
• 235000010443 alginic acid Nutrition 0.000 description 3
• 229920000615 alginic acid Polymers 0.000 description 3
• 125000004183 alkoxy alkyl group Chemical group 0.000 description 3
• 125000003282 alkyl amino group Chemical group 0.000 description 3
• 125000004202 aminomethyl group Chemical group [H]N([H])C([H])([H])* 0.000 description 3
• 230000033115 angiogenesis Effects 0.000 description 3
• 230000000259 anti-tumor effect Effects 0.000 description 3
• 125000004104 aryloxy group Chemical group 0.000 description 3
• 235000010233 benzoic acid Nutrition 0.000 description 3
• 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 3
• 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 3
• 235000010290 biphenyl Nutrition 0.000 description 3
• 239000004305 biphenyl Substances 0.000 description 3
• GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 3
• 229910052794 bromium Inorganic materials 0.000 description 3
• 239000011575 calcium Substances 0.000 description 3
• 239000001913 cellulose Substances 0.000 description 3
• 239000000460 chlorine Substances 0.000 description 3
• 229910052801 chlorine Inorganic materials 0.000 description 3
• 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 3
• 230000034994 death Effects 0.000 description 3
• 231100000517 death Toxicity 0.000 description 3
• 238000001514 detection method Methods 0.000 description 3
• 239000003937 drug carrier Substances 0.000 description 3
• 239000012634 fragment Substances 0.000 description 3
• 230000014509 gene expression Effects 0.000 description 3
• 239000008103 glucose Substances 0.000 description 3
• 230000012010 growth Effects 0.000 description 3
• 239000005556 hormone Substances 0.000 description 3
• 229940088597 hormone Drugs 0.000 description 3
• 150000004677 hydrates Chemical class 0.000 description 3
• 150000002431 hydrogen Chemical class 0.000 description 3
• 239000001257 hydrogen Substances 0.000 description 3
• JXXWJMUPNZDILL-UHFFFAOYSA-N imidazo[4,5-b]pyridin-2-one Chemical compound C1=CC=NC2=NC(=O)N=C21 JXXWJMUPNZDILL-UHFFFAOYSA-N 0.000 description 3
• 238000001727 in vivo Methods 0.000 description 3
• 125000004531 indol-5-yl group Chemical group [H]N1C([H])=C([H])C2=C([H])C(*)=C([H])C([H])=C12 0.000 description 3
• 125000000842 isoxazolyl group Chemical group 0.000 description 3
• 235000019359 magnesium stearate Nutrition 0.000 description 3
• 230000003211 malignant effect Effects 0.000 description 3
• 125000002950 monocyclic group Chemical group 0.000 description 3
• 125000002757 morpholinyl group Chemical group 0.000 description 3
• 231100000252 nontoxic Toxicity 0.000 description 3
• 230000003000 nontoxic effect Effects 0.000 description 3
• 125000002971 oxazolyl group Chemical group 0.000 description 3
• 239000000546 pharmaceutical excipient Substances 0.000 description 3
• 125000003367 polycyclic group Chemical group 0.000 description 3
• 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 3
• 229920000136 polysorbate Polymers 0.000 description 3
• 229920000053 polysorbate 80 Polymers 0.000 description 3
• 239000013641 positive control Substances 0.000 description 3
• 239000000843 powder Substances 0.000 description 3
• 239000002243 precursor Substances 0.000 description 3
• 238000002203 pretreatment Methods 0.000 description 3
• 125000003373 pyrazinyl group Chemical group 0.000 description 3
• 125000002098 pyridazinyl group Chemical group 0.000 description 3
• 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 3
• 238000011160 research Methods 0.000 description 3
• 238000012552 review Methods 0.000 description 3
• 125000006413 ring segment Chemical group 0.000 description 3
• 231100000279 safety data Toxicity 0.000 description 3
• 230000035945 sensitivity Effects 0.000 description 3
• 230000019491 signal transduction Effects 0.000 description 3
• 238000011301 standard therapy Methods 0.000 description 3
• 239000005720 sucrose Substances 0.000 description 3
• 239000000829 suppository Substances 0.000 description 3
• 230000009885 systemic effect Effects 0.000 description 3
• 239000000454 talc Substances 0.000 description 3
• 229910052623 talc Inorganic materials 0.000 description 3
• 235000012222 talc Nutrition 0.000 description 3
• 125000003831 tetrazolyl group Chemical group 0.000 description 3
• 125000000335 thiazolyl group Chemical group 0.000 description 3
• 125000001544 thienyl group Chemical group 0.000 description 3
• 238000002877 time resolved fluorescence resonance energy transfer Methods 0.000 description 3
• 230000001988 toxicity Effects 0.000 description 3
• 231100000419 toxicity Toxicity 0.000 description 3
• 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 3
• 208000009999 tuberous sclerosis Diseases 0.000 description 3
• 230000035899 viability Effects 0.000 description 3
• 229920002554 vinyl polymer Polymers 0.000 description 3
• 239000001993 wax Substances 0.000 description 3
• 238000001262 western blot Methods 0.000 description 3
• JXKZMTFKUWWBQF-QGZVFWFLSA-N (2R)-2-(cyclohexylmethyl)-5-[4-(1H-1,2,4-triazol-5-yl)phenyl]-1,2-dihydropyrazine Chemical compound N1N=CN=C1C1=CC=C(C=C1)C1=CN[C@@H](C=N1)CC1CCCCC1 JXKZMTFKUWWBQF-QGZVFWFLSA-N 0.000 description 2
• GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 2
• QYMGRIFMUQCAJW-UHFFFAOYSA-N 1,2-dihydropyrazine Chemical compound C1NC=CN=C1 QYMGRIFMUQCAJW-UHFFFAOYSA-N 0.000 description 2
• CKTSBUTUHBMZGZ-SHYZEUOFSA-N 2'‐deoxycytidine Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 CKTSBUTUHBMZGZ-SHYZEUOFSA-N 0.000 description 2
• JXKZMTFKUWWBQF-UHFFFAOYSA-N 2-(cyclohexylmethyl)-5-[4-(1H-1,2,4-triazol-5-yl)phenyl]-1,2-dihydropyrazine Chemical compound C(C1CCCCC1)C1NC=C(N=C1)C1=CC=C(C=C1)C1=NN=CN1 JXKZMTFKUWWBQF-UHFFFAOYSA-N 0.000 description 2
• JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
• 125000004182 2-chlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(*)C([H])=C1[H] 0.000 description 2
• NRRUPCJJALELBB-UHFFFAOYSA-N 3-(2-morpholin-4-yl-2-oxoethyl)-5-[4-(1h-1,2,4-triazol-5-yl)phenyl]-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound C1COCCN1C(=O)CN(C(NC1=NC=2)=O)C1=NC=2C(C=C1)=CC=C1C1=NN=CN1 NRRUPCJJALELBB-UHFFFAOYSA-N 0.000 description 2
• LJGHYPLBDBRCRZ-UHFFFAOYSA-N 3-(3-aminophenyl)sulfonylaniline Chemical group NC1=CC=CC(S(=O)(=O)C=2C=C(N)C=CC=2)=C1 LJGHYPLBDBRCRZ-UHFFFAOYSA-N 0.000 description 2
• FWVUGLOSPMVGRD-UHFFFAOYSA-N 3-(cyclohexylmethyl)-5-[6-(2-hydroxypropan-2-yl)pyridin-3-yl]-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound C1=NC(C(C)(O)C)=CC=C1C1=CN=C(NC(=O)N2CC3CCCCC3)C2=N1 FWVUGLOSPMVGRD-UHFFFAOYSA-N 0.000 description 2
• FTMIABDXGIBHQJ-CYBMUJFWSA-N 3-[(1r)-1-phenylethyl]-5-[4-(1h-1,2,4-triazol-5-yl)phenyl]-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound C1([C@@H](C)N2C(NC3=NC=C(N=C32)C=2C=CC(=CC=2)C2=NNC=N2)=O)=CC=CC=C1 FTMIABDXGIBHQJ-CYBMUJFWSA-N 0.000 description 2
• FPGGLMIYNLQOID-UHFFFAOYSA-N 3h-pyridin-2-one Chemical compound O=C1CC=CC=N1 FPGGLMIYNLQOID-UHFFFAOYSA-N 0.000 description 2
• ZKGAOAZZVMIQSV-UHFFFAOYSA-N 4-[1-[(3-methoxyphenyl)methyl]-2H-pyrazin-5-yl]phenol Chemical compound OC1=CC=C(C=C1)C1=CN(CC=N1)CC1=CC(=CC=C1)OC ZKGAOAZZVMIQSV-UHFFFAOYSA-N 0.000 description 2
• 125000004801 4-cyanophenyl group Chemical group [H]C1=C([H])C(C#N)=C([H])C([H])=C1* 0.000 description 2
• DAERFROLXKHWOB-UHFFFAOYSA-N 5-(2-aminopyrimidin-5-yl)-3-(cyclohexylmethyl)-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound C1=NC(N)=NC=C1C1=CN=C(NC(=O)N2CC3CCCCC3)C2=N1 DAERFROLXKHWOB-UHFFFAOYSA-N 0.000 description 2
• NMUSYJAQQFHJEW-UHFFFAOYSA-N 5-Azacytidine Natural products O=C1N=C(N)N=CN1C1C(O)C(O)C(CO)O1 NMUSYJAQQFHJEW-UHFFFAOYSA-N 0.000 description 2
• 125000004938 5-pyridyl group Chemical group N1=CC=CC(=C1)* 0.000 description 2
• WFAMMNCUHVZQKK-UHFFFAOYSA-N 8,9-dihydro-7h-purine-6-carboxamide Chemical compound NC(=O)C1=NC=NC2=C1NCN2 WFAMMNCUHVZQKK-UHFFFAOYSA-N 0.000 description 2
• VTSCFUAJBOFZEI-UHFFFAOYSA-N 8-oxo-9-phenyl-2-pyridin-3-yl-7h-purine-6-carboxamide Chemical compound O=C1NC=2C(C(=O)N)=NC(C=3C=NC=CC=3)=NC=2N1C1=CC=CC=C1 VTSCFUAJBOFZEI-UHFFFAOYSA-N 0.000 description 2
• DXHKTHGKGVIGTC-UHFFFAOYSA-N 9-(2-hydroxyethyl)-2-(trifluoromethyl)purine-6-carboxamide Chemical compound NC(=O)C1=NC(C(F)(F)F)=NC2=C1N=CN2CCO DXHKTHGKGVIGTC-UHFFFAOYSA-N 0.000 description 2
• SEBCRFUXBLJQHQ-UHFFFAOYSA-N 9-(2-hydroxyethyl)-2-methylpurine-6-carboxamide Chemical compound CC1=NC(C(N)=O)=C2N=CN(CCO)C2=N1 SEBCRFUXBLJQHQ-UHFFFAOYSA-N 0.000 description 2
• MWKDGWKQVQCNGG-UHFFFAOYSA-N 9-(2-hydroxyethyl)-2-phenylpurine-6-carboxamide Chemical compound N=1C=2N(CCO)C=NC=2C(C(=O)N)=NC=1C1=CC=CC=C1 MWKDGWKQVQCNGG-UHFFFAOYSA-N 0.000 description 2
• FBECNQNZSXSUKI-UHFFFAOYSA-N 9-(2-hydroxyethyl)-2-prop-1-enylpurine-6-carboxamide Chemical compound CC=CC1=NC(C(N)=O)=C2N=CN(CCO)C2=N1 FBECNQNZSXSUKI-UHFFFAOYSA-N 0.000 description 2
• QVVNOYDJHDGIMD-UHFFFAOYSA-N 9-(3-hydroxypropyl)-2-(trifluoromethyl)purine-6-carboxamide Chemical compound NC(=O)C1=NC(C(F)(F)F)=NC2=C1N=CN2CCCO QVVNOYDJHDGIMD-UHFFFAOYSA-N 0.000 description 2
• FPQGZRGCTSQXCL-UHFFFAOYSA-N 9-(3-hydroxypropyl)-2-methylpurine-6-carboxamide Chemical compound CC1=NC(C(N)=O)=C2N=CN(CCCO)C2=N1 FPQGZRGCTSQXCL-UHFFFAOYSA-N 0.000 description 2
• OCXWDXMLAQPCKK-UHFFFAOYSA-N 9-benzylpurine-2,6-dicarboxamide Chemical compound C12=NC(C(=O)N)=NC(C(N)=O)=C2N=CN1CC1=CC=CC=C1 OCXWDXMLAQPCKK-UHFFFAOYSA-N 0.000 description 2
• QGZKDVFQNNGYKY-OUBTZVSYSA-N Ammonia-15N Chemical compound [15NH3] QGZKDVFQNNGYKY-OUBTZVSYSA-N 0.000 description 2
• IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
• BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 2
• 206010006895 Cachexia Diseases 0.000 description 2
• OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
• VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
• OKTJSMMVPCPJKN-OUBTZVSYSA-N Carbon-13 Chemical compound [13C] OKTJSMMVPCPJKN-OUBTZVSYSA-N 0.000 description 2
• UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 2
• 230000007067 DNA methylation Effects 0.000 description 2
• CKTSBUTUHBMZGZ-UHFFFAOYSA-N Deoxycytidine Natural products O=C1N=C(N)C=CN1C1OC(CO)C(O)C1 CKTSBUTUHBMZGZ-UHFFFAOYSA-N 0.000 description 2
• YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 2
• 102000004190 Enzymes Human genes 0.000 description 2
• 108090000790 Enzymes Proteins 0.000 description 2
• JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 2
• HKVAMNSJSFKALM-GKUWKFKPSA-N Everolimus Chemical compound C1C[C@@H](OCCO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 HKVAMNSJSFKALM-GKUWKFKPSA-N 0.000 description 2
• 229930091371 Fructose Natural products 0.000 description 2
• 239000005715 Fructose Substances 0.000 description 2
• RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 2
• 108010010803 Gelatin Proteins 0.000 description 2
• DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
• UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
• AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 2
• FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
• 241000124008 Mammalia Species 0.000 description 2
• 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
• 241000699666 Mus <mouse, genus> Species 0.000 description 2
• ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 2
• CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 2
• MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 2
• 150000001204 N-oxides Chemical class 0.000 description 2
• NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
• ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
• 208000006265 Renal cell carcinoma Diseases 0.000 description 2
• DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
• NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
• CBPNZQVSJQDFBE-FUXHJELOSA-N Temsirolimus Chemical compound C1C[C@@H](OC(=O)C(C)(CO)CO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 CBPNZQVSJQDFBE-FUXHJELOSA-N 0.000 description 2
• DHXVGJBLRPWPCS-UHFFFAOYSA-N Tetrahydropyran Chemical compound C1CCOCC1 DHXVGJBLRPWPCS-UHFFFAOYSA-N 0.000 description 2
• ZMZDMBWJUHKJPS-UHFFFAOYSA-M Thiocyanate anion Chemical compound [S-]C#N ZMZDMBWJUHKJPS-UHFFFAOYSA-M 0.000 description 2
• JEIVYJHYJKISIY-UHFFFAOYSA-N [2-(benzoyloxymethyl)-3-(6-carbamoyl-2-methylpurin-9-yl)cyclobutyl]methyl benzoate Chemical compound C12=NC(C)=NC(C(N)=O)=C2N=CN1C(C1COC(=O)C=2C=CC=CC=2)CC1COC(=O)C1=CC=CC=C1 JEIVYJHYJKISIY-UHFFFAOYSA-N 0.000 description 2
• ZUSWDTWYONAOPH-UHFFFAOYSA-N [2-(trifluoromethyl)phenyl]hydrazine;hydrochloride Chemical group [Cl-].[NH3+]NC1=CC=CC=C1C(F)(F)F ZUSWDTWYONAOPH-UHFFFAOYSA-N 0.000 description 2
• 230000002159 abnormal effect Effects 0.000 description 2
• 150000007513 acids Chemical class 0.000 description 2
• 230000009471 action Effects 0.000 description 2
• 230000004913 activation Effects 0.000 description 2
• 239000000654 additive Substances 0.000 description 2
• 125000005426 adeninyl group Chemical group N1=C(N=C2N=CNC2=C1N)* 0.000 description 2
• 150000001299 aldehydes Chemical class 0.000 description 2
• 150000001409 amidines Chemical class 0.000 description 2
• 229950000242 ancitabine Drugs 0.000 description 2
• 230000001093 anti-cancer Effects 0.000 description 2
• 238000011319 anticancer therapy Methods 0.000 description 2
• 229940045988 antineoplastic drug protein kinase inhibitors Drugs 0.000 description 2
• 239000007864 aqueous solution Substances 0.000 description 2
• QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
• 125000005602 azabenzimidazolyl group Chemical group 0.000 description 2
• 125000005334 azaindolyl group Chemical group N1N=C(C2=CC=CC=C12)* 0.000 description 2
• 150000001540 azides Chemical class 0.000 description 2
• 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 2
• 125000005874 benzothiadiazolyl group Chemical group 0.000 description 2
• 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 2
• 125000003354 benzotriazolyl group Chemical group N1N=NC2=C1C=CC=C2* 0.000 description 2
• WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
• 239000000872 buffer Substances 0.000 description 2
• 229910052791 calcium Inorganic materials 0.000 description 2
• 239000001506 calcium phosphate Substances 0.000 description 2
• 229910000389 calcium phosphate Inorganic materials 0.000 description 2
• 235000011010 calcium phosphates Nutrition 0.000 description 2
• 239000004202 carbamide Substances 0.000 description 2
• 229910052799 carbon Inorganic materials 0.000 description 2
• 150000003857 carboxamides Chemical class 0.000 description 2
• 230000010261 cell growth Effects 0.000 description 2
• 230000004663 cell proliferation Effects 0.000 description 2
• 230000003833 cell viability Effects 0.000 description 2
• 230000033077 cellular process Effects 0.000 description 2
• 230000005754 cellular signaling Effects 0.000 description 2
• 230000008859 change Effects 0.000 description 2
• 238000006243 chemical reaction Methods 0.000 description 2
• 239000007910 chewable tablet Substances 0.000 description 2
• 229940110456 cocoa butter Drugs 0.000 description 2
• 235000019868 cocoa butter Nutrition 0.000 description 2
• DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 2
• XLJMAIOERFSOGZ-UHFFFAOYSA-M cyanate Chemical compound [O-]C#N XLJMAIOERFSOGZ-UHFFFAOYSA-M 0.000 description 2
• JHIVVAPYMSGYDF-UHFFFAOYSA-N cyclohexanone Chemical compound O=C1CCCCC1 JHIVVAPYMSGYDF-UHFFFAOYSA-N 0.000 description 2
• AUELWJRRASQDKI-UHFFFAOYSA-N cyclohexyl carbamate Chemical compound NC(=O)OC1CCCCC1 AUELWJRRASQDKI-UHFFFAOYSA-N 0.000 description 2
• 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 2
• 229960000684 cytarabine Drugs 0.000 description 2
• 230000003831 deregulation Effects 0.000 description 2
• 229910052805 deuterium Inorganic materials 0.000 description 2
• 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 description 2
• SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 description 2
• 238000004090 dissolution Methods 0.000 description 2
• 229960003668 docetaxel Drugs 0.000 description 2
• 239000002552 dosage form Substances 0.000 description 2
• 231100000673 dose–response relationship Toxicity 0.000 description 2
• 150000002081 enamines Chemical class 0.000 description 2
• 229960005167 everolimus Drugs 0.000 description 2
• NMUSYJAQQFHJEW-ARQDHWQXSA-N fazarabine Chemical compound O=C1N=C(N)N=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 NMUSYJAQQFHJEW-ARQDHWQXSA-N 0.000 description 2
• 238000011049 filling Methods 0.000 description 2
• 125000002541 furyl group Chemical group 0.000 description 2
• 239000008273 gelatin Substances 0.000 description 2
• 229920000159 gelatin Polymers 0.000 description 2
• 235000019322 gelatine Nutrition 0.000 description 2
• 235000011852 gelatine desserts Nutrition 0.000 description 2
• 230000002068 genetic effect Effects 0.000 description 2
• 230000002489 hematologic effect Effects 0.000 description 2
• 150000007857 hydrazones Chemical class 0.000 description 2
• ZMZDMBWJUHKJPS-UHFFFAOYSA-N hydrogen thiocyanate Natural products SC#N ZMZDMBWJUHKJPS-UHFFFAOYSA-N 0.000 description 2
• 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 2
• 125000000336 imidazol-5-yl group Chemical group [H]N1C([H])=NC([H])=C1[*] 0.000 description 2
• 125000002632 imidazolidinyl group Chemical group 0.000 description 2
• 125000005945 imidazopyridyl group Chemical group 0.000 description 2
• 150000003949 imides Chemical class 0.000 description 2
• 150000002466 imines Chemical class 0.000 description 2
• 238000002513 implantation Methods 0.000 description 2
• 238000000338 in vitro Methods 0.000 description 2
• 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 description 2
• 230000003993 interaction Effects 0.000 description 2
• 239000000543 intermediate Substances 0.000 description 2
• PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 2
• 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 2
• 239000012948 isocyanate Substances 0.000 description 2
• 150000002513 isocyanates Chemical class 0.000 description 2
• 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
• 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 2
• 150000002540 isothiocyanates Chemical class 0.000 description 2
• 150000002576 ketones Chemical class 0.000 description 2
• 210000004072 lung Anatomy 0.000 description 2
• 229910052749 magnesium Inorganic materials 0.000 description 2
• 238000012423 maintenance Methods 0.000 description 2
• 230000007246 mechanism Effects 0.000 description 2
• 230000004060 metabolic process Effects 0.000 description 2
• HNQIVZYLYMDVSB-UHFFFAOYSA-N methanesulfonimidic acid Chemical compound CS(N)(=O)=O HNQIVZYLYMDVSB-UHFFFAOYSA-N 0.000 description 2
• LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
• 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
• 229940016286 microcrystalline cellulose Drugs 0.000 description 2
• 239000008108 microcrystalline cellulose Substances 0.000 description 2
• 150000007522 mineralic acids Chemical class 0.000 description 2
• 230000004048 modification Effects 0.000 description 2
• 238000012986 modification Methods 0.000 description 2
• 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
• 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
• 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
• 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 2
• 239000002777 nucleoside Substances 0.000 description 2
• 125000003835 nucleoside group Chemical group 0.000 description 2
• 150000007524 organic acids Chemical class 0.000 description 2
• AICOOMRHRUFYCM-ZRRPKQBOSA-N oxazine, 1 Chemical compound C([C@@H]1[C@H](C(C[C@]2(C)[C@@H]([C@H](C)N(C)C)[C@H](O)C[C@]21C)=O)CC1=CC2)C[C@H]1[C@@]1(C)[C@H]2N=C(C(C)C)OC1 AICOOMRHRUFYCM-ZRRPKQBOSA-N 0.000 description 2
• 150000002923 oximes Chemical class 0.000 description 2
• 239000001301 oxygen Substances 0.000 description 2
• 125000000636 p-nitrophenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)[N+]([O-])=O 0.000 description 2
• 238000007911 parenteral administration Methods 0.000 description 2
• 230000002085 persistent effect Effects 0.000 description 2
• UEZVMMHDMIWARA-UHFFFAOYSA-M phosphonate Chemical compound [O-]P(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-M 0.000 description 2
• 229910000073 phosphorus hydride Inorganic materials 0.000 description 2
• 125000004193 piperazinyl group Chemical group 0.000 description 2
• 125000005936 piperidyl group Chemical group 0.000 description 2
• 239000011591 potassium Substances 0.000 description 2
• 229910052700 potassium Inorganic materials 0.000 description 2
• 238000011321 prophylaxis Methods 0.000 description 2
• 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
• QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
• 239000003909 protein kinase inhibitor Substances 0.000 description 2
• 230000009822 protein phosphorylation Effects 0.000 description 2
• DDSCCYSKFCZQMP-UHFFFAOYSA-N purine-6-caboxamide Chemical compound NC(=O)C1=NC=NC2=C1N=CN2 DDSCCYSKFCZQMP-UHFFFAOYSA-N 0.000 description 2
• HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 description 2
• 125000000719 pyrrolidinyl group Chemical group 0.000 description 2
• 125000000168 pyrrolyl group Chemical group 0.000 description 2
• 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 2
• 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 2
• 230000002285 radioactive effect Effects 0.000 description 2
• 238000011084 recovery Methods 0.000 description 2
• 102200048955 rs121434569 Human genes 0.000 description 2
• 238000012163 sequencing technique Methods 0.000 description 2
• 210000002966 serum Anatomy 0.000 description 2
• 239000011780 sodium chloride Substances 0.000 description 2
• 235000019333 sodium laurylsulphate Nutrition 0.000 description 2
• 239000002904 solvent Substances 0.000 description 2
• 210000002784 stomach Anatomy 0.000 description 2
• 125000005346 substituted cycloalkyl group Chemical group 0.000 description 2
• 239000000758 substrate Substances 0.000 description 2
• 150000008163 sugars Chemical class 0.000 description 2
• 229940124530 sulfonamide Drugs 0.000 description 2
• 150000003456 sulfonamides Chemical class 0.000 description 2
• 150000003457 sulfones Chemical class 0.000 description 2
• 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 2
• 239000011593 sulfur Substances 0.000 description 2
• 239000002511 suppository base Substances 0.000 description 2
• 238000012353 t test Methods 0.000 description 2
• 239000007916 tablet composition Substances 0.000 description 2
• 229960000235 temsirolimus Drugs 0.000 description 2
• QFJCIRLUMZQUOT-UHFFFAOYSA-N temsirolimus Natural products C1CC(O)C(OC)CC1CC(C)C1OC(=O)C2CCCCN2C(=O)C(=O)C(O)(O2)C(C)CCC2CC(OC)C(C)=CC=CC=CC(C)CC(C)C(=O)C(OC)C(O)C(C)=CC(C)C(=O)C1 QFJCIRLUMZQUOT-UHFFFAOYSA-N 0.000 description 2
• 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
• 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 2
• 125000001412 tetrahydropyranyl group Chemical group 0.000 description 2
• 125000000147 tetrahydroquinolinyl group Chemical group N1(CCCC2=CC=CC=C12)* 0.000 description 2
• 125000002813 thiocarbonyl group Chemical group *C(*)=S 0.000 description 2
• 150000003568 thioethers Chemical class 0.000 description 2
• 150000003573 thiols Chemical class 0.000 description 2
• 238000011269 treatment regimen Methods 0.000 description 2
• QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
• 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 2
• 239000000439 tumor marker Substances 0.000 description 2
• 231100000402 unacceptable toxicity Toxicity 0.000 description 2
• 230000009385 viral infection Effects 0.000 description 2
• NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 1
• 125000006273 (C1-C3) alkyl group Chemical group 0.000 description 1
• 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 1
• VQTIKTKQDPEAQY-UHFFFAOYSA-N 1-(2-methoxyethyl)-5-[4-(1H-1,2,4-triazol-5-yl)phenyl]-2H-pyrazine Chemical compound N=1N=C(NC=1)C1=CC=C(C=C1)C1=CN(CC=N1)CCOC VQTIKTKQDPEAQY-UHFFFAOYSA-N 0.000 description 1
• RGIRAMBPYYWIFF-UHFFFAOYSA-N 1-(5-tert-butyl-2-methoxyphenyl)-3-[4-(2-oxo-3,4-dihydro-1h-pyrido[2,3-b]pyrazin-7-yl)naphthalen-1-yl]urea Chemical compound COC1=CC=C(C(C)(C)C)C=C1NC(=O)NC(C1=CC=CC=C11)=CC=C1C1=CN=C(NCC(=O)N2)C2=C1 RGIRAMBPYYWIFF-UHFFFAOYSA-N 0.000 description 1
• CEPWLUZYNCRCNS-OAHLLOKOSA-N 1-[(1r)-1-phenylethyl]-6-quinolin-5-yl-3h-imidazo[4,5-b]pyridin-2-one Chemical compound C1([C@@H](C)N2C(NC3=NC=C(C=C32)C=2C3=CC=CN=C3C=CC=2)=O)=CC=CC=C1 CEPWLUZYNCRCNS-OAHLLOKOSA-N 0.000 description 1
• RPQZTTQVRYEKCR-UHFFFAOYSA-N 1-[3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one Chemical compound OC1C(O)C(CO)OC1N1C(=O)N=CC=C1 RPQZTTQVRYEKCR-UHFFFAOYSA-N 0.000 description 1
• 125000006432 1-methyl cyclopropyl group Chemical group [H]C([H])([H])C1(*)C([H])([H])C1([H])[H] 0.000 description 1
• JBDILTKRCGFYLW-HNNXBMFYSA-N 1-methyl-3-[(1s)-1-phenylethyl]-5-quinolin-5-ylimidazo[4,5-b]pyrazin-2-one Chemical compound C1([C@H](C)N2C(N(C)C3=NC=C(N=C32)C=2C3=CC=CN=C3C=CC=2)=O)=CC=CC=C1 JBDILTKRCGFYLW-HNNXBMFYSA-N 0.000 description 1
• 125000001637 1-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C(*)=C([H])C([H])=C([H])C2=C1[H] 0.000 description 1
• NGQIDWQPIXGRGH-UHFFFAOYSA-N 1h-pyrazin-2-one;dihydrochloride Chemical compound Cl.Cl.O=C1C=NC=CN1 NGQIDWQPIXGRGH-UHFFFAOYSA-N 0.000 description 1
• 125000004201 2,4-dichlorophenyl group Chemical group [H]C1=C([H])C(*)=C(Cl)C([H])=C1Cl 0.000 description 1
• 125000004215 2,4-difluorophenyl group Chemical group [H]C1=C([H])C(*)=C(F)C([H])=C1F 0.000 description 1
• MOHLKOBIHZUNKX-UHFFFAOYSA-N 2-(1h-imidazo[4,5-b]pyridin-6-yl)-8-oxo-9-(2-propan-2-ylphenyl)-7h-purine-6-carboxamide Chemical compound CC(C)C1=CC=CC=C1N1C(=O)NC2=C(C(N)=O)N=C(C=3C=C4NC=NC4=NC=3)N=C21 MOHLKOBIHZUNKX-UHFFFAOYSA-N 0.000 description 1
• SAPUJGILULUQBA-UHFFFAOYSA-N 2-(2-hydroxyphenyl)-9-(2-methoxyphenyl)purine-6-carboxamide Chemical compound COC1=CC=CC=C1N1C2=NC(C=3C(=CC=CC=3)O)=NC(C(N)=O)=C2N=C1 SAPUJGILULUQBA-UHFFFAOYSA-N 0.000 description 1
• RIABHLXVSQJTOF-UHFFFAOYSA-N 2-(2-methoxypyridin-3-yl)-8-oxo-9-phenyl-7h-purine-6-carboxamide Chemical compound COC1=NC=CC=C1C1=NC(C(N)=O)=C(NC(=O)N2C=3C=CC=CC=3)C2=N1 RIABHLXVSQJTOF-UHFFFAOYSA-N 0.000 description 1
• XSPKQLPEYNLKJR-UHFFFAOYSA-N 2-(3-cyanophenyl)-8-oxo-9-phenyl-7h-purine-6-carboxamide Chemical compound O=C1NC=2C(C(=O)N)=NC(C=3C=C(C=CC=3)C#N)=NC=2N1C1=CC=CC=C1 XSPKQLPEYNLKJR-UHFFFAOYSA-N 0.000 description 1
• VKBNVPXLCNOFDA-UHFFFAOYSA-N 2-(3-hydroxyanilino)-9-(2-methoxyphenyl)purine-6-carboxamide Chemical compound COC1=CC=CC=C1N1C2=NC(NC=3C=C(O)C=CC=3)=NC(C(N)=O)=C2N=C1 VKBNVPXLCNOFDA-UHFFFAOYSA-N 0.000 description 1
• REKXWQDSPQOUAG-UHFFFAOYSA-N 2-(3-hydroxyphenyl)-9-(2-methoxyphenyl)purine-6-carboxamide Chemical compound COC1=CC=CC=C1N1C2=NC(C=3C=C(O)C=CC=3)=NC(C(N)=O)=C2N=C1 REKXWQDSPQOUAG-UHFFFAOYSA-N 0.000 description 1
• UCIWKRFNWOZMJV-UHFFFAOYSA-N 2-(3-hydroxyphenyl)-9-(2-methylpropyl)-8-oxo-7h-purine-6-carboxamide Chemical compound N=1C(C(N)=O)=C2NC(=O)N(CC(C)C)C2=NC=1C1=CC=CC(O)=C1 UCIWKRFNWOZMJV-UHFFFAOYSA-N 0.000 description 1
• XRNLNXMBIPHBES-UHFFFAOYSA-N 2-(3h-benzimidazol-5-yl)-3h-benzimidazole-5-carboxamide Chemical compound C1=C2NC=NC2=CC(C=2NC3=CC=C(C=C3N=2)C(=O)N)=C1 XRNLNXMBIPHBES-UHFFFAOYSA-N 0.000 description 1
• YMTNFIVNOUHQSD-UHFFFAOYSA-N 2-(4-cyanophenyl)-8-oxo-9-phenyl-7h-purine-6-carboxamide Chemical compound O=C1NC=2C(C(=O)N)=NC(C=3C=CC(=CC=3)C#N)=NC=2N1C1=CC=CC=C1 YMTNFIVNOUHQSD-UHFFFAOYSA-N 0.000 description 1
• RSIHMCRNLBDGEN-UHFFFAOYSA-N 2-(8-oxo-2-phenyl-7h-purin-9-yl)acetic acid Chemical compound N=1C=C2NC(=O)N(CC(=O)O)C2=NC=1C1=CC=CC=C1 RSIHMCRNLBDGEN-UHFFFAOYSA-N 0.000 description 1
• IZXIZTKNFFYFOF-UHFFFAOYSA-N 2-Oxazolidone Chemical class O=C1NCCO1 IZXIZTKNFFYFOF-UHFFFAOYSA-N 0.000 description 1
• WZDXGZWPBKNKQP-UHFFFAOYSA-N 2-[4-(imidazol-1-ylmethyl)anilino]-9-(2-methoxyphenyl)-8-oxo-7h-purine-6-carboxamide Chemical compound COC1=CC=CC=C1N1C(=O)NC2=C(C(N)=O)N=C(NC=3C=CC(CN4C=NC=C4)=CC=3)N=C21 WZDXGZWPBKNKQP-UHFFFAOYSA-N 0.000 description 1
• PJTQQEBZJCYPSX-UHFFFAOYSA-N 2-[4-[1-(oxan-4-ylmethyl)-2H-pyrazin-5-yl]phenyl]propan-2-ol Chemical compound OC(C)(C)C1=CC=C(C=C1)C1=CN(CC=N1)CC1CCOCC1 PJTQQEBZJCYPSX-UHFFFAOYSA-N 0.000 description 1
• MVZBIMBJTYQZBA-UHFFFAOYSA-N 2-[5-[1-(2,2-dimethylpropyl)-2H-pyrazin-5-yl]pyridin-2-yl]propan-2-ol Chemical compound CC(C)(C)CN1CC=NC(=C1)C1=CC=C(N=C1)C(C)(C)O MVZBIMBJTYQZBA-UHFFFAOYSA-N 0.000 description 1
• JAIBITQUJGCXDB-UHFFFAOYSA-N 2-[5-[1-(2-morpholin-4-ylethyl)-2H-pyrazin-5-yl]pyridin-2-yl]propan-2-ol Chemical compound CC(C)(O)C1=CC=C(C=N1)C1=CN(CCN2CCOCC2)CC=N1 JAIBITQUJGCXDB-UHFFFAOYSA-N 0.000 description 1
• GYPMCFHSTCTYRV-UHFFFAOYSA-N 2-[5-[1-(2-phenylethyl)-2H-pyrazin-5-yl]pyridin-2-yl]propan-2-ol Chemical compound OC(C)(C)C1=CC=C(C=N1)C1=CN(CC=N1)CCC1=CC=CC=C1 GYPMCFHSTCTYRV-UHFFFAOYSA-N 0.000 description 1
• YTBJMPWPJNTECW-UHFFFAOYSA-N 2-[5-[1-(3-methoxypropyl)-2h-pyrazin-5-yl]pyridin-2-yl]propan-2-ol Chemical compound COCCCN1CC=NC(C=2C=NC(=CC=2)C(C)(C)O)=C1 YTBJMPWPJNTECW-UHFFFAOYSA-N 0.000 description 1
• GYKRHWFQEUPOCW-UHFFFAOYSA-N 2-[5-[1-(cyclohexylmethyl)-2H-pyrazin-5-yl]pyridin-2-yl]propan-2-ol Chemical compound CC(C)(O)C1=CC=C(C=N1)C1=CN(CC2CCCCC2)CC=N1 GYKRHWFQEUPOCW-UHFFFAOYSA-N 0.000 description 1
• WSXACIXIKNSFCD-UHFFFAOYSA-N 2-[5-[1-(cyclopropylmethyl)-2H-pyrazin-5-yl]pyridin-2-yl]propan-2-ol Chemical compound C1(CC1)CN1CC=NC(=C1)C=1C=NC(=CC=1)C(C)(C)O WSXACIXIKNSFCD-UHFFFAOYSA-N 0.000 description 1
• REVPVEFRHLAUNF-UHFFFAOYSA-N 2-[5-[1-(oxan-4-ylmethyl)-2h-pyrazin-5-yl]pyridin-2-yl]propan-2-ol Chemical compound C1=NC(C(C)(O)C)=CC=C1C(N=CC1)=CN1CC1CCOCC1 REVPVEFRHLAUNF-UHFFFAOYSA-N 0.000 description 1
• FHYHXDVRIKIWDD-UHFFFAOYSA-N 2-[5-[1-[2-(oxan-3-yl)ethyl]-2H-pyrazin-5-yl]pyridin-2-yl]propan-2-ol Chemical compound OC(C)(C)C1=CC=C(C=N1)C1=CN(CC=N1)CCC1COCCC1 FHYHXDVRIKIWDD-UHFFFAOYSA-N 0.000 description 1
• CVKYVILXFJFGSU-GDBMZVCRSA-N 2-[5-[1-[[(1R,3R)-3-methoxycyclopentyl]methyl]-2H-pyrazin-5-yl]pyridin-2-yl]propan-2-ol Chemical compound OC(C)(C)C1=CC=C(C=N1)C1=CN(CC=N1)C[C@H]1C[C@@H](CC1)OC CVKYVILXFJFGSU-GDBMZVCRSA-N 0.000 description 1
• MPDKOGQMQLSNOF-GBNDHIKLSA-N 2-amino-5-[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1h-pyrimidin-6-one Chemical compound O=C1NC(N)=NC=C1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 MPDKOGQMQLSNOF-GBNDHIKLSA-N 0.000 description 1
• PPDPUIRKDSCCFN-UHFFFAOYSA-N 2-benzofuran-1,3-diimine Chemical compound C1=CC=C2C(=N)OC(=N)C2=C1 PPDPUIRKDSCCFN-UHFFFAOYSA-N 0.000 description 1
• 125000004974 2-butenyl group Chemical group C(C=CC)* 0.000 description 1
• 125000006040 2-hexenyl group Chemical group 0.000 description 1
• 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 description 1
• JZOPHJLRUKZARE-UHFFFAOYSA-N 2-methyl-5-[2-methyl-4-(1H-1,2,4-triazol-5-yl)phenyl]-1-[2-(oxan-4-yl)ethyl]-2H-pyrazine Chemical compound CC1C=NC(=CN1CCC1CCOCC1)C1=C(C=C(C=C1)C1=NN=CN1)C JZOPHJLRUKZARE-UHFFFAOYSA-N 0.000 description 1
• FROWTTVEPOUWQS-UHFFFAOYSA-N 2-methyl-6-(1h-1,2,4-triazol-5-yl)pyridine Chemical compound CC1=CC=CC(C2=NNC=N2)=N1 FROWTTVEPOUWQS-UHFFFAOYSA-N 0.000 description 1
• CZUXUTZOEIRAGY-UHFFFAOYSA-N 2-methyl-8-oxo-9-phenyl-7h-purine-6-carboxamide Chemical compound C12=NC(C)=NC(C(N)=O)=C2NC(=O)N1C1=CC=CC=C1 CZUXUTZOEIRAGY-UHFFFAOYSA-N 0.000 description 1
• 125000005916 2-methylpentyl group Chemical group 0.000 description 1
• NVMATPIZWPTLIH-UHFFFAOYSA-N 2-phenyl-7,9-dihydropurin-8-one Chemical compound N1C=C2NC(=O)N=C2N=C1C1=CC=CC=C1 NVMATPIZWPTLIH-UHFFFAOYSA-N 0.000 description 1
• 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
• 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
• LUZJNRNNOOBBDY-UHFFFAOYSA-N 2-pyridin-2-ylpropan-2-ol Chemical compound CC(C)(O)C1=CC=CC=N1 LUZJNRNNOOBBDY-UHFFFAOYSA-N 0.000 description 1
• 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 1
• NUPHYZNYMCUIFJ-UHFFFAOYSA-N 3-(1-phenylethyl)-5-quinolin-4-yl-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound C12=NC(C=3C4=CC=CC=C4N=CC=3)=CN=C2NC(=O)N1C(C)C1=CC=CC=C1 NUPHYZNYMCUIFJ-UHFFFAOYSA-N 0.000 description 1
• KHUDFKOMPUTJHV-UHFFFAOYSA-N 3-(1-phenylethyl)-5-quinolin-5-yl-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound C12=NC(C=3C4=CC=CN=C4C=CC=3)=CN=C2NC(=O)N1C(C)C1=CC=CC=C1 KHUDFKOMPUTJHV-UHFFFAOYSA-N 0.000 description 1
• LFUAZCRRROSASB-UHFFFAOYSA-N 3-(1-phenylethyl)-5-quinolin-5-yl-1h-imidazo[4,5-b]pyridin-2-one Chemical compound C12=NC(C=3C4=CC=CN=C4C=CC=3)=CC=C2NC(=O)N1C(C)C1=CC=CC=C1 LFUAZCRRROSASB-UHFFFAOYSA-N 0.000 description 1
• KTEZHJVSVXJQGB-UHFFFAOYSA-N 3-(1-phenylethyl)-5-quinolin-6-yl-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound C12=NC(C=3C=C4C=CC=NC4=CC=3)=CN=C2NC(=O)N1C(C)C1=CC=CC=C1 KTEZHJVSVXJQGB-UHFFFAOYSA-N 0.000 description 1
• SKIWQHRZDIRSSR-UHFFFAOYSA-N 3-(1h-indazol-6-yl)-5-(2-methoxyethyl)-7,8-dihydropyrazino[2,3-b]pyrazin-6-one Chemical compound C1=C2C=NNC2=CC(C2=CN=C3NCC(=O)N(C3=N2)CCOC)=C1 SKIWQHRZDIRSSR-UHFFFAOYSA-N 0.000 description 1
• HTOCMIQLIPPYMM-UHFFFAOYSA-N 3-(2-hydroxyethyl)-5-(2-methoxy-5-propan-2-ylphenyl)-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound COC1=CC=C(C(C)C)C=C1C1=CN=C(NC(=O)N2CCO)C2=N1 HTOCMIQLIPPYMM-UHFFFAOYSA-N 0.000 description 1
• UWGGCVWPZPWUJI-UHFFFAOYSA-N 3-(2-hydroxyethyl)-5-(4-hydroxyphenyl)-1H-imidazo[4,5-b]pyrazin-2-one Chemical compound C=1N=C2NC(=O)N(CCO)C2=NC=1C1=CC=C(O)C=C1 UWGGCVWPZPWUJI-UHFFFAOYSA-N 0.000 description 1
• WLGSCAIGYWPKMK-UHFFFAOYSA-N 3-(cyclohexylmethyl)-5-(1h-pyrazol-5-yl)-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound O=C1NC2=NC=C(C=3NN=CC=3)N=C2N1CC1CCCCC1 WLGSCAIGYWPKMK-UHFFFAOYSA-N 0.000 description 1
• MDCNFFXUJKMFRH-UHFFFAOYSA-N 3-(cyclohexylmethyl)-5-(2-methoxy-5-propan-2-ylphenyl)-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound COC1=CC=C(C(C)C)C=C1C1=CN=C(NC(=O)N2CC3CCCCC3)C2=N1 MDCNFFXUJKMFRH-UHFFFAOYSA-N 0.000 description 1
• BWYPXDIMFQJVTN-UHFFFAOYSA-N 3-(cyclohexylmethyl)-5-(2-methoxypyridin-4-yl)-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound C1=NC(OC)=CC(C=2N=C3N(CC4CCCCC4)C(=O)NC3=NC=2)=C1 BWYPXDIMFQJVTN-UHFFFAOYSA-N 0.000 description 1
• SZUGKOACIOLZEX-UHFFFAOYSA-N 3-(cyclohexylmethyl)-5-(2-oxo-1,3-dihydroindol-5-yl)-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound C=1C=C2NC(=O)CC2=CC=1C(N=C12)=CN=C1NC(=O)N2CC1CCCCC1 SZUGKOACIOLZEX-UHFFFAOYSA-N 0.000 description 1
• JMLNCVGLQXECPM-UHFFFAOYSA-N 3-(cyclohexylmethyl)-5-(2-oxo-1,3-dihydroindol-6-yl)-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound C1=C2NC(=O)CC2=CC=C1C(N=C12)=CN=C1NC(=O)N2CC1CCCCC1 JMLNCVGLQXECPM-UHFFFAOYSA-N 0.000 description 1
• KKNIQSPXTAJAKL-UHFFFAOYSA-N 3-(cyclohexylmethyl)-5-(4-hydroxy-2-methylphenyl)-1H-imidazo[4,5-b]pyrazin-2-one Chemical compound CC1=CC(O)=CC=C1C1=CN=C(NC(=O)N2CC3CCCCC3)C2=N1 KKNIQSPXTAJAKL-UHFFFAOYSA-N 0.000 description 1
• HHPDRWBCLDJWTP-UHFFFAOYSA-N 3-(cyclohexylmethyl)-5-(4-imidazol-1-ylphenyl)-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound O=C1NC2=NC=C(C=3C=CC(=CC=3)N3C=NC=C3)N=C2N1CC1CCCCC1 HHPDRWBCLDJWTP-UHFFFAOYSA-N 0.000 description 1
• NCTXOQVCFIYCSU-UHFFFAOYSA-N 3-(cyclohexylmethyl)-5-(6-methoxypyridin-3-yl)-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound C1=NC(OC)=CC=C1C1=CN=C(NC(=O)N2CC3CCCCC3)C2=N1 NCTXOQVCFIYCSU-UHFFFAOYSA-N 0.000 description 1
• BWFBLSMKLIDEEE-UHFFFAOYSA-N 3-(cyclohexylmethyl)-5-[2-(2-methoxyethylamino)pyrimidin-5-yl]-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound C1=NC(NCCOC)=NC=C1C1=CN=C(NC(=O)N2CC3CCCCC3)C2=N1 BWFBLSMKLIDEEE-UHFFFAOYSA-N 0.000 description 1
• CGSJJFWISCGFKU-UHFFFAOYSA-N 3-(cyclohexylmethyl)-5-[2-(methylamino)pyrimidin-5-yl]-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound C1=NC(NC)=NC=C1C1=CN=C(NC(=O)N2CC3CCCCC3)C2=N1 CGSJJFWISCGFKU-UHFFFAOYSA-N 0.000 description 1
• GJLLXBAFMTVTAF-UHFFFAOYSA-N 3-(cyclohexylmethyl)-5-[3-(1h-1,2,4-triazol-5-yl)phenyl]-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound O=C1NC2=NC=C(C=3C=C(C=CC=3)C3=NNC=N3)N=C2N1CC1CCCCC1 GJLLXBAFMTVTAF-UHFFFAOYSA-N 0.000 description 1
• CFMIKFFITYIZAA-UHFFFAOYSA-N 3-(cyclohexylmethyl)-5-[4-(1h-1,2,4-triazol-5-yl)phenyl]-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound O=C1NC2=NC=C(C=3C=CC(=CC=3)C3=NNC=N3)N=C2N1CC1CCCCC1 CFMIKFFITYIZAA-UHFFFAOYSA-N 0.000 description 1
• BHPWHRPVZOWBAN-UHFFFAOYSA-N 3-(cyclohexylmethyl)-5-[4-(2-hydroxypropan-2-yl)phenyl]-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound C1=CC(C(C)(O)C)=CC=C1C1=CN=C(NC(=O)N2CC3CCCCC3)C2=N1 BHPWHRPVZOWBAN-UHFFFAOYSA-N 0.000 description 1
• NNGMJGUIHOKDNH-UHFFFAOYSA-N 3-(cyclohexylmethyl)-5-[4-(2h-tetrazol-5-yl)phenyl]-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound O=C1NC2=NC=C(C=3C=CC(=CC=3)C3=NNN=N3)N=C2N1CC1CCCCC1 NNGMJGUIHOKDNH-UHFFFAOYSA-N 0.000 description 1
• VWMRRGITEQHWJA-UHFFFAOYSA-N 3-(cyclohexylmethyl)-5-[4-(5-methyl-1h-1,2,4-triazol-3-yl)phenyl]-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound N1C(C)=NC(C=2C=CC(=CC=2)C=2N=C3N(CC4CCCCC4)C(=O)NC3=NC=2)=N1 VWMRRGITEQHWJA-UHFFFAOYSA-N 0.000 description 1
• XERLYFQBPNSINL-UHFFFAOYSA-N 3-(cyclohexylmethyl)-5-[4-(hydroxymethyl)phenyl]-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound C1=CC(CO)=CC=C1C1=CN=C(NC(=O)N2CC3CCCCC3)C2=N1 XERLYFQBPNSINL-UHFFFAOYSA-N 0.000 description 1
• RQSUJEWZKKTMQG-UHFFFAOYSA-N 3-(cyclohexylmethyl)-5-[4-(triazol-1-yl)phenyl]-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound O=C1NC2=NC=C(C=3C=CC(=CC=3)N3N=NC=C3)N=C2N1CC1CCCCC1 RQSUJEWZKKTMQG-UHFFFAOYSA-N 0.000 description 1
• YZDJFWPJJBQFGI-UHFFFAOYSA-N 3-(cyclohexylmethyl)-5-[4-[5-(trifluoromethyl)-1h-1,2,4-triazol-3-yl]phenyl]-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound N1C(C(F)(F)F)=NC(C=2C=CC(=CC=2)C=2N=C3N(CC4CCCCC4)C(=O)NC3=NC=2)=N1 YZDJFWPJJBQFGI-UHFFFAOYSA-N 0.000 description 1
• DYPAWPXIWPUQON-UHFFFAOYSA-N 3-(cyclohexylmethyl)-5-phenyl-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound O=C1NC2=NC=C(C=3C=CC=CC=3)N=C2N1CC1CCCCC1 DYPAWPXIWPUQON-UHFFFAOYSA-N 0.000 description 1
• BRPKRMNEDQAYAY-UHFFFAOYSA-N 3-(cyclohexylmethyl)-5-pyridin-2-yl-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound O=C1NC2=NC=C(C=3N=CC=CC=3)N=C2N1CC1CCCCC1 BRPKRMNEDQAYAY-UHFFFAOYSA-N 0.000 description 1
• VLDWUBVXCBQALE-UHFFFAOYSA-N 3-(cyclohexylmethyl)-5-pyridin-3-yl-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound O=C1NC2=NC=C(C=3C=NC=CC=3)N=C2N1CC1CCCCC1 VLDWUBVXCBQALE-UHFFFAOYSA-N 0.000 description 1
• FUCYFCCSZXARSC-UHFFFAOYSA-N 3-(cyclohexylmethyl)-5-pyridin-4-yl-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound O=C1NC2=NC=C(C=3C=CN=CC=3)N=C2N1CC1CCCCC1 FUCYFCCSZXARSC-UHFFFAOYSA-N 0.000 description 1
• SDSKKSXAVZBIAN-UHFFFAOYSA-N 3-(cyclopentylmethyl)-5-quinolin-5-yl-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound O=C1NC2=NC=C(C=3C4=CC=CN=C4C=CC=3)N=C2N1CC1CCCC1 SDSKKSXAVZBIAN-UHFFFAOYSA-N 0.000 description 1
• DPLBRXNWXNJZRA-UHFFFAOYSA-N 3-(cyclopropylmethyl)-5-(2-methoxy-5-propan-2-ylphenyl)-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound COC1=CC=C(C(C)C)C=C1C1=CN=C(NC(=O)N2CC3CC3)C2=N1 DPLBRXNWXNJZRA-UHFFFAOYSA-N 0.000 description 1
• USIZAOCKUYIISW-UHFFFAOYSA-N 3-(oxan-3-yl)-5-quinolin-5-yl-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound O=C1NC2=NC=C(C=3C4=CC=CN=C4C=CC=3)N=C2N1C1CCCOC1 USIZAOCKUYIISW-UHFFFAOYSA-N 0.000 description 1
• IJGOUGXLJVQAIN-UHFFFAOYSA-N 3-(oxan-4-yl)-5-quinolin-5-yl-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound O=C1NC2=NC=C(C=3C4=CC=CN=C4C=CC=3)N=C2N1C1CCOCC1 IJGOUGXLJVQAIN-UHFFFAOYSA-N 0.000 description 1
• RPYCPMGUICEQGN-UHFFFAOYSA-N 3-(piperidin-4-ylmethyl)-5-quinolin-5-yl-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound O=C1NC2=NC=C(C=3C4=CC=CN=C4C=CC=3)N=C2N1CC1CCNCC1 RPYCPMGUICEQGN-UHFFFAOYSA-N 0.000 description 1
• GXTJPCRFZLLAQY-SECBINFHSA-N 3-[(1r)-1-phenylethyl]-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound C1([C@@H](C)N2C(NC3=NC=CN=C32)=O)=CC=CC=C1 GXTJPCRFZLLAQY-SECBINFHSA-N 0.000 description 1
• LFUAZCRRROSASB-OAHLLOKOSA-N 3-[(1r)-1-phenylethyl]-5-quinolin-5-yl-1h-imidazo[4,5-b]pyridin-2-one Chemical compound C1([C@@H](C)N2C(NC3=CC=C(N=C32)C=2C3=CC=CN=C3C=CC=2)=O)=CC=CC=C1 LFUAZCRRROSASB-OAHLLOKOSA-N 0.000 description 1
• DIZWAEYOHSAAHB-HXUWFJFHSA-N 3-[(1r)-1-phenylpropyl]-5-quinolin-5-yl-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound C1([C@@H](CC)N2C(NC3=NC=C(N=C32)C=2C3=CC=CN=C3C=CC=2)=O)=CC=CC=C1 DIZWAEYOHSAAHB-HXUWFJFHSA-N 0.000 description 1
• LPHOVUYRCJSZPO-IBGZPJMESA-N 3-[(1r)-2-hydroxy-1-phenylethyl]-5-quinolin-5-yl-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound C1([C@H](CO)N2C(NC3=NC=C(N=C32)C=2C3=CC=CN=C3C=CC=2)=O)=CC=CC=C1 LPHOVUYRCJSZPO-IBGZPJMESA-N 0.000 description 1
• GXTJPCRFZLLAQY-VIFPVBQESA-N 3-[(1s)-1-phenylethyl]-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound C1([C@H](C)N2C(NC3=NC=CN=C32)=O)=CC=CC=C1 GXTJPCRFZLLAQY-VIFPVBQESA-N 0.000 description 1
• KHUDFKOMPUTJHV-AWEZNQCLSA-N 3-[(1s)-1-phenylethyl]-5-quinolin-5-yl-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound C1([C@H](C)N2C(NC3=NC=C(N=C32)C=2C3=CC=CN=C3C=CC=2)=O)=CC=CC=C1 KHUDFKOMPUTJHV-AWEZNQCLSA-N 0.000 description 1
• DIZWAEYOHSAAHB-FQEVSTJZSA-N 3-[(1s)-1-phenylpropyl]-5-quinolin-5-yl-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound C1([C@H](CC)N2C(NC3=NC=C(N=C32)C=2C3=CC=CN=C3C=CC=2)=O)=CC=CC=C1 DIZWAEYOHSAAHB-FQEVSTJZSA-N 0.000 description 1
• TWFWQSRQIAZZLO-INIZCTEOSA-N 3-[(2r)-1-hydroxy-3-methylbutan-2-yl]-5-(2-methoxy-5-propan-2-ylphenyl)-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound COC1=CC=C(C(C)C)C=C1C1=CN=C(NC(=O)N2[C@@H](CO)C(C)C)C2=N1 TWFWQSRQIAZZLO-INIZCTEOSA-N 0.000 description 1
• RJIVOEPSWUCCQO-INIZCTEOSA-N 3-[(2r)-1-hydroxy-3-methylbutan-2-yl]-5-quinolin-5-yl-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound C1=CC=C2C(C=3N=C4N(C(NC4=NC=3)=O)[C@@H](CO)C(C)C)=CC=CC2=N1 RJIVOEPSWUCCQO-INIZCTEOSA-N 0.000 description 1
• TWFWQSRQIAZZLO-MRXNPFEDSA-N 3-[(2s)-1-hydroxy-3-methylbutan-2-yl]-5-(2-methoxy-5-propan-2-ylphenyl)-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound COC1=CC=C(C(C)C)C=C1C1=CN=C(NC(=O)N2[C@H](CO)C(C)C)C2=N1 TWFWQSRQIAZZLO-MRXNPFEDSA-N 0.000 description 1
• OWGBICBGEABZQX-GOSISDBHSA-N 3-[(2s)-1-hydroxy-3-methylbutan-2-yl]-5-(2-methoxy-5-propan-2-ylphenyl)-1h-imidazo[4,5-b]pyridin-2-one Chemical compound COC1=CC=C(C(C)C)C=C1C1=CC=C(NC(=O)N2[C@H](CO)C(C)C)C2=N1 OWGBICBGEABZQX-GOSISDBHSA-N 0.000 description 1
• ADDMRECUTDRQOF-UHFFFAOYSA-N 3-[(3-methoxyphenyl)methyl]-5-(4-methylsulfonylphenyl)-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound COC1=CC=CC(CN2C(NC3=NC=C(N=C32)C=2C=CC(=CC=2)S(C)(=O)=O)=O)=C1 ADDMRECUTDRQOF-UHFFFAOYSA-N 0.000 description 1
• ZSQGOJJYLYQHLY-UHFFFAOYSA-N 3-[1-(3-fluorophenyl)ethyl]-5-quinolin-5-yl-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound C12=NC(C=3C4=CC=CN=C4C=CC=3)=CN=C2NC(=O)N1C(C)C1=CC=CC(F)=C1 ZSQGOJJYLYQHLY-UHFFFAOYSA-N 0.000 description 1
• QTHBKIPNRPDTTR-UHFFFAOYSA-N 3-[1-(3-methoxyphenyl)ethyl]-5-quinolin-5-yl-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound COC1=CC=CC(C(C)N2C(NC3=NC=C(N=C32)C=2C3=CC=CN=C3C=CC=2)=O)=C1 QTHBKIPNRPDTTR-UHFFFAOYSA-N 0.000 description 1
• CNUDCVPOVFWLOM-UHFFFAOYSA-N 3-[1-(4-chlorophenyl)ethyl]-5-quinolin-5-yl-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound C12=NC(C=3C4=CC=CN=C4C=CC=3)=CN=C2NC(=O)N1C(C)C1=CC=C(Cl)C=C1 CNUDCVPOVFWLOM-UHFFFAOYSA-N 0.000 description 1
• AARQHDYJCCUDOH-UHFFFAOYSA-N 3-[1-(4-methylsulfonylphenyl)ethyl]-5-quinolin-5-yl-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound C12=NC(C=3C4=CC=CN=C4C=CC=3)=CN=C2NC(=O)N1C(C)C1=CC=C(S(C)(=O)=O)C=C1 AARQHDYJCCUDOH-UHFFFAOYSA-N 0.000 description 1
• WAFIIPCUXMSTHV-UHFFFAOYSA-N 3-[2-(dimethylamino)ethyl]-5-(3,4,5-trimethoxyphenyl)-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound COC1=C(OC)C(OC)=CC(C=2N=C3N(CCN(C)C)C(=O)NC3=NC=2)=C1 WAFIIPCUXMSTHV-UHFFFAOYSA-N 0.000 description 1
• FLJFLRPENIKSPA-UHFFFAOYSA-N 3-[2-(oxan-4-yl)ethyl]-5-(4-pyrrolidin-2-ylphenyl)-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound O=C1NC2=NC=C(C=3C=CC(=CC=3)C3NCCC3)N=C2N1CCC1CCOCC1 FLJFLRPENIKSPA-UHFFFAOYSA-N 0.000 description 1
• KPLIWPOLIXIVDS-UHFFFAOYSA-N 3-[2-(oxan-4-yl)ethyl]-5-(4-pyrrolidin-3-ylphenyl)-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound O=C1NC2=NC=C(C=3C=CC(=CC=3)C3CNCC3)N=C2N1CCC1CCOCC1 KPLIWPOLIXIVDS-UHFFFAOYSA-N 0.000 description 1
• OIOIEFYEDXUNPK-UHFFFAOYSA-N 3-[2-(oxan-4-yl)ethyl]-5-[4-(5-oxopyrrolidin-2-yl)phenyl]-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound N1C(=O)CCC1C1=CC=C(C=2N=C3N(CCC4CCOCC4)C(=O)NC3=NC=2)C=C1 OIOIEFYEDXUNPK-UHFFFAOYSA-N 0.000 description 1
• WVSLRWFLPGLENR-UHFFFAOYSA-N 3-[2-methyl-4-(1h-1,2,4-triazol-5-yl)phenyl]-5-[2-(oxan-4-yl)ethyl]-7,8-dihydropyrazino[2,3-b]pyrazin-6-one Chemical compound CC1=CC(C2=NNC=N2)=CC=C1C(N=C12)=CN=C1NCC(=O)N2CCC1CCOCC1 WVSLRWFLPGLENR-UHFFFAOYSA-N 0.000 description 1
• HYNXATWPOPIBJD-UHFFFAOYSA-N 3-[2-methyl-4-(1h-1,2,4-triazol-5-yl)phenyl]-7,8-dihydro-5h-pyrazino[2,3-b]pyrazin-6-one Chemical compound C=1C=C(C=2N=C3NC(=O)CNC3=NC=2)C(C)=CC=1C1=NN=CN1 HYNXATWPOPIBJD-UHFFFAOYSA-N 0.000 description 1
• GCVDTBDFHANTQU-UHFFFAOYSA-N 3-[3-fluoro-4-(1h-1,2,4-triazol-5-yl)phenyl]-5-[2-(oxan-4-yl)ethyl]-7,8-dihydropyrazino[2,3-b]pyrazin-6-one Chemical compound FC1=CC(C=2N=C3N(CCC4CCOCC4)C(=O)CNC3=NC=2)=CC=C1C1=NN=CN1 GCVDTBDFHANTQU-UHFFFAOYSA-N 0.000 description 1
• DZUZGHMCJFXRHJ-UHFFFAOYSA-N 3-[4-(2-hydroxypropan-2-yl)phenyl]-5-(2-methoxyethyl)-7,8-dihydropyrazino[2,3-b]pyrazin-6-one Chemical compound N1=C2N(CCOC)C(=O)CNC2=NC=C1C1=CC=C(C(C)(C)O)C=C1 DZUZGHMCJFXRHJ-UHFFFAOYSA-N 0.000 description 1
• WSNKEJIFARPOSQ-UHFFFAOYSA-N 3-[4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl]oxy-N-(1-benzothiophen-2-ylmethyl)benzamide Chemical compound NCC1=CC(=NC(=C1)C(F)(F)F)OC=1C=C(C(=O)NCC2=CC3=C(S2)C=CC=C3)C=CC=1 WSNKEJIFARPOSQ-UHFFFAOYSA-N 0.000 description 1
• OUEFEFGOKIPWCD-UHFFFAOYSA-N 3-[5-fluoro-2-methyl-4-(1h-1,2,4-triazol-5-yl)phenyl]-5-[2-(oxan-4-yl)ethyl]-7,8-dihydropyrazino[2,3-b]pyrazin-6-one Chemical compound FC=1C=C(C=2N=C3N(CCC4CCOCC4)C(=O)CNC3=NC=2)C(C)=CC=1C1=NN=CN1 OUEFEFGOKIPWCD-UHFFFAOYSA-N 0.000 description 1
• XSQAJVDTZWOBMX-UHFFFAOYSA-N 3-[6-(2-hydroxypropan-2-yl)pyridin-3-yl]-5-(2-methoxyethyl)-7,8-dihydropyrazino[2,3-b]pyrazin-6-one Chemical compound N1=C2N(CCOC)C(=O)CNC2=NC=C1C1=CC=C(C(C)(C)O)N=C1 XSQAJVDTZWOBMX-UHFFFAOYSA-N 0.000 description 1
• TUHIMPAVUZMPBC-UHFFFAOYSA-N 3-[6-(2-hydroxypropan-2-yl)pyridin-3-yl]-5-(2-morpholin-4-ylethyl)-7,8-dihydropyrazino[2,3-b]pyrazin-6-one Chemical compound C1=NC(C(C)(O)C)=CC=C1C1=CN=C(NCC(=O)N2CCN3CCOCC3)C2=N1 TUHIMPAVUZMPBC-UHFFFAOYSA-N 0.000 description 1
• IHCVPLCAIWFKAI-UHFFFAOYSA-N 3-[6-(2-hydroxypropan-2-yl)pyridin-3-yl]-5-(oxan-4-yl)-7,8-dihydropyrazino[2,3-b]pyrazin-6-one Chemical compound C1=NC(C(C)(O)C)=CC=C1C1=CN=C(NCC(=O)N2C3CCOCC3)C2=N1 IHCVPLCAIWFKAI-UHFFFAOYSA-N 0.000 description 1
• WEVYNIUIFUYDGI-UHFFFAOYSA-N 3-[6-[4-(trifluoromethoxy)anilino]-4-pyrimidinyl]benzamide Chemical compound NC(=O)C1=CC=CC(C=2N=CN=C(NC=3C=CC(OC(F)(F)F)=CC=3)C=2)=C1 WEVYNIUIFUYDGI-UHFFFAOYSA-N 0.000 description 1
• BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
• ZPKIIKLGZKVLEC-UHFFFAOYSA-N 3-benzhydryl-5-quinolin-5-yl-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound O=C1NC2=NC=C(C=3C4=CC=CN=C4C=CC=3)N=C2N1C(C=1C=CC=CC=1)C1=CC=CC=C1 ZPKIIKLGZKVLEC-UHFFFAOYSA-N 0.000 description 1
• ICFDZIRYJSCARC-UHFFFAOYSA-N 3-cyclopentyl-5-(4-hydroxyphenyl)-1H-imidazo[4,5-b]pyrazin-2-one Chemical compound C1=CC(O)=CC=C1C1=CN=C(NC(=O)N2C3CCCC3)C2=N1 ICFDZIRYJSCARC-UHFFFAOYSA-N 0.000 description 1
• 125000004180 3-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(F)=C1[H] 0.000 description 1
• 125000006041 3-hexenyl group Chemical group 0.000 description 1
• VCUQYGADRBYVIF-UHFFFAOYSA-N 3-phenyl-5-quinolin-5-yl-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound O=C1NC2=NC=C(C=3C4=CC=CN=C4C=CC=3)N=C2N1C1=CC=CC=C1 VCUQYGADRBYVIF-UHFFFAOYSA-N 0.000 description 1
• OMPYYRPNIOTCAN-UHFFFAOYSA-N 3-propan-2-yl-1,2-dihydropyrazine Chemical compound C1=CN=C(CN1)C(C)C OMPYYRPNIOTCAN-UHFFFAOYSA-N 0.000 description 1
• FNCKQRKZSWHIST-UHFFFAOYSA-N 3-propan-2-yl-5-quinolin-5-yl-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound C1=CC=C2C(C=3N=C4N(C(NC4=NC=3)=O)C(C)C)=CC=CC2=N1 FNCKQRKZSWHIST-UHFFFAOYSA-N 0.000 description 1
• QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
• IDYKCXHJJGMAEV-RRKCRQDMSA-N 4-amino-5-fluoro-1-[(2r,4s,5r)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one Chemical compound C1=C(F)C(N)=NC(=O)N1[C@@H]1O[C@H](CO)[C@@H](O)C1 IDYKCXHJJGMAEV-RRKCRQDMSA-N 0.000 description 1
• GAMYYCRTACQSBR-UHFFFAOYSA-N 4-azabenzimidazole Chemical compound C1=CC=C2NC=NC2=N1 GAMYYCRTACQSBR-UHFFFAOYSA-N 0.000 description 1
• JBNHYROKRGEFJO-UHFFFAOYSA-N 4-methyl-2-(1h-1,2,4-triazol-5-yl)pyridine Chemical compound CC1=CC=NC(C=2NN=CN=2)=C1 JBNHYROKRGEFJO-UHFFFAOYSA-N 0.000 description 1
• YUDPTGPSBJVHCN-DZQJYWQESA-N 4-methylumbelliferyl beta-D-galactoside Chemical compound C1=CC=2C(C)=CC(=O)OC=2C=C1O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O YUDPTGPSBJVHCN-DZQJYWQESA-N 0.000 description 1
• LLBZPESJRQGYMB-UHFFFAOYSA-N 4-one Natural products O1C(C(=O)CC)CC(C)C11C2(C)CCC(C3(C)C(C(C)(CO)C(OC4C(C(O)C(O)C(COC5C(C(O)C(O)CO5)OC5C(C(OC6C(C(O)C(O)C(CO)O6)O)C(O)C(CO)O5)OC5C(C(O)C(O)C(C)O5)O)O4)O)CC3)CC3)=C3C2(C)CC1 LLBZPESJRQGYMB-UHFFFAOYSA-N 0.000 description 1
• 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 1
• NSPMIYGKQJPBQR-UHFFFAOYSA-N 4H-1,2,4-triazole Chemical compound C=1N=CNN=1 NSPMIYGKQJPBQR-UHFFFAOYSA-N 0.000 description 1
• FZWCKMZSFGGKEH-UHFFFAOYSA-N 5-(1h-imidazo[4,5-b]pyridin-6-yl)-3-(oxan-4-ylmethyl)-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound O=C1NC2=NC=C(C=3C=C4N=CNC4=NC=3)N=C2N1CC1CCOCC1 FZWCKMZSFGGKEH-UHFFFAOYSA-N 0.000 description 1
• SYIJRJBXBTYBEZ-UHFFFAOYSA-N 5-(2-fluorophenyl)-3-(1-phenylethyl)-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound C12=NC(C=3C(=CC=CC=3)F)=CN=C2NC(=O)N1C(C)C1=CC=CC=C1 SYIJRJBXBTYBEZ-UHFFFAOYSA-N 0.000 description 1
• KESYHKLQEITDQJ-CYBMUJFWSA-N 5-(2-methoxy-5-propan-2-ylphenyl)-3-[(2r)-3-methylbutan-2-yl]-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound COC1=CC=C(C(C)C)C=C1C1=CN=C(NC(=O)N2[C@H](C)C(C)C)C2=N1 KESYHKLQEITDQJ-CYBMUJFWSA-N 0.000 description 1
• JLQWEBMTAPURRM-CYBMUJFWSA-N 5-(2-methoxy-5-propan-2-ylphenyl)-3-[(3r)-oxolan-3-yl]-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound COC1=CC=C(C(C)C)C=C1C1=CN=C(NC(=O)N2[C@H]3COCC3)C2=N1 JLQWEBMTAPURRM-CYBMUJFWSA-N 0.000 description 1
• JLQWEBMTAPURRM-ZDUSSCGKSA-N 5-(2-methoxy-5-propan-2-ylphenyl)-3-[(3s)-oxolan-3-yl]-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound COC1=CC=C(C(C)C)C=C1C1=CN=C(NC(=O)N2[C@@H]3COCC3)C2=N1 JLQWEBMTAPURRM-ZDUSSCGKSA-N 0.000 description 1
• OMPIISLASYMVQK-UHFFFAOYSA-N 5-(2-methoxy-5-propan-2-ylphenyl)-3-propan-2-yl-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound COC1=CC=C(C(C)C)C=C1C1=CN=C(NC(=O)N2C(C)C)C2=N1 OMPIISLASYMVQK-UHFFFAOYSA-N 0.000 description 1
• FSPTUMMDZLMOBH-UHFFFAOYSA-N 5-(2-methoxyphenyl)-3-propan-2-yl-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound COC1=CC=CC=C1C1=CN=C(NC(=O)N2C(C)C)C2=N1 FSPTUMMDZLMOBH-UHFFFAOYSA-N 0.000 description 1
• PWWWAFNIOCQDNC-UHFFFAOYSA-N 5-(3-fluorophenyl)-3-(1-phenylethyl)-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound C12=NC(C=3C=C(F)C=CC=3)=CN=C2NC(=O)N1C(C)C1=CC=CC=C1 PWWWAFNIOCQDNC-UHFFFAOYSA-N 0.000 description 1
• SXFSVQGLVPFKRK-UHFFFAOYSA-N 5-(3-hydroxyphenyl)-3-(2-methoxyphenyl)-1h-imidazo[4,5-b]pyridin-2-one Chemical compound COC1=CC=CC=C1N1C(=O)NC2=CC=C(C=3C=C(O)C=CC=3)N=C21 SXFSVQGLVPFKRK-UHFFFAOYSA-N 0.000 description 1
• ARAFZLNEXXVYMQ-UHFFFAOYSA-N 5-(3h-benzimidazol-5-yl)-3-(cyclohexylmethyl)-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound O=C1NC2=NC=C(C=3C=C4N=CNC4=CC=3)N=C2N1CC1CCCCC1 ARAFZLNEXXVYMQ-UHFFFAOYSA-N 0.000 description 1
• FELWYCRJYMPKOR-UHFFFAOYSA-N 5-(3h-benzimidazol-5-yl)-3-[2-(oxan-4-yl)ethyl]-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound O=C1NC2=NC=C(C=3C=C4N=CNC4=CC=3)N=C2N1CCC1CCOCC1 FELWYCRJYMPKOR-UHFFFAOYSA-N 0.000 description 1
• JZKBZHHHTWFSEL-UHFFFAOYSA-N 5-(4-hydroxyphenyl)-3-(2-morpholin-4-ylethyl)-1H-imidazo[4,5-b]pyrazin-2-one hydrochloride Chemical compound Cl.C1=CC(O)=CC=C1C1=CN=C(NC(=O)N2CCN3CCOCC3)C2=N1 JZKBZHHHTWFSEL-UHFFFAOYSA-N 0.000 description 1
• RYQIOZIGGZLCGI-UHFFFAOYSA-N 5-(4-hydroxyphenyl)-3-(3-methoxypropyl)-1H-imidazo[4,5-b]pyrazin-2-one Chemical compound C=1N=C2NC(=O)N(CCCOC)C2=NC=1C1=CC=C(O)C=C1 RYQIOZIGGZLCGI-UHFFFAOYSA-N 0.000 description 1
• YUAGNXNKUXHFTR-UHFFFAOYSA-N 5-(4-hydroxyphenyl)-3-(pyrrolidin-2-ylmethyl)-1H-imidazo[4,5-b]pyrazin-2-one hydrochloride Chemical compound Cl.C1=CC(O)=CC=C1C1=CN=C(NC(=O)N2CC3NCCC3)C2=N1 YUAGNXNKUXHFTR-UHFFFAOYSA-N 0.000 description 1
• UWQROPYNVNJYIY-UHFFFAOYSA-N 5-(4-hydroxyphenyl)-3-[(1-methylpiperidin-3-yl)methyl]-1H-imidazo[4,5-b]pyrazin-2-one Chemical compound C1N(C)CCCC1CN1C(=O)NC2=NC=C(C=3C=CC(O)=CC=3)N=C21 UWQROPYNVNJYIY-UHFFFAOYSA-N 0.000 description 1
• SVABQAKNYVESNJ-UHFFFAOYSA-N 5-(4-hydroxyphenyl)-3-[2-(oxan-4-yl)ethyl]-1H-imidazo[4,5-b]pyrazin-2-one Chemical compound C1=CC(O)=CC=C1C1=CN=C(NC(=O)N2CCC3CCOCC3)C2=N1 SVABQAKNYVESNJ-UHFFFAOYSA-N 0.000 description 1
• CWIXLTRPVKXNRI-UHFFFAOYSA-N 5-(6-fluoropyridin-3-yl)-3-(oxan-4-ylmethyl)-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound C1=NC(F)=CC=C1C1=CN=C(NC(=O)N2CC3CCOCC3)C2=N1 CWIXLTRPVKXNRI-UHFFFAOYSA-N 0.000 description 1
• RSGNOWXSFSNENG-UHFFFAOYSA-N 5-(cyclopentylmethyl)-3-[6-(2-hydroxypropan-2-yl)pyridin-3-yl]-7,8-dihydropyrazino[2,3-b]pyrazin-6-one Chemical compound C1=NC(C(C)(O)C)=CC=C1C1=CN=C(NCC(=O)N2CC3CCCC3)C2=N1 RSGNOWXSFSNENG-UHFFFAOYSA-N 0.000 description 1
• SYPJBUDABPWWFC-UHFFFAOYSA-N 5-[3-(dimethylamino)phenyl]-3-(1-phenylethyl)-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound C12=NC(C=3C=C(C=CC=3)N(C)C)=CN=C2NC(=O)N1C(C)C1=CC=CC=C1 SYPJBUDABPWWFC-UHFFFAOYSA-N 0.000 description 1
• FJICUYATBKVLIM-UHFFFAOYSA-N 5-[3-(hydroxymethyl)thiophen-2-yl]-3-(oxan-4-ylmethyl)-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound C1=CSC(C=2N=C3N(CC4CCOCC4)C(=O)NC3=NC=2)=C1CO FJICUYATBKVLIM-UHFFFAOYSA-N 0.000 description 1
• XWHFFSGLSKQYDD-UHFFFAOYSA-N 5-[4-(1H-1,2,4-triazol-5-yl)phenyl]-1-[[3-(trifluoromethyl)phenyl]methyl]-2H-pyrazine Chemical compound N=1N=C(NC=1)C1=CC=C(C=C1)C1=CN(CC=N1)CC1=CC(=CC=C1)C(F)(F)F XWHFFSGLSKQYDD-UHFFFAOYSA-N 0.000 description 1
• IIMPGCAGKKFHHU-UHFFFAOYSA-N 5-[4-(2-hydroxypropan-2-yl)phenyl]-3-(oxan-4-ylmethyl)-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound C1=CC(C(C)(O)C)=CC=C1C1=CN=C(NC(=O)N2CC3CCOCC3)C2=N1 IIMPGCAGKKFHHU-UHFFFAOYSA-N 0.000 description 1
• RXGMTZODXXTWTD-UHFFFAOYSA-N 5-[4-(4,5-dimethyl-1h-imidazol-2-yl)phenyl]-3-(2-morpholin-4-ylethyl)-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound N1C(C)=C(C)N=C1C1=CC=C(C=2N=C3N(CCN4CCOCC4)C(=O)NC3=NC=2)C=C1 RXGMTZODXXTWTD-UHFFFAOYSA-N 0.000 description 1
• FDOGTFDCNZSVTD-UHFFFAOYSA-N 5-[4-(4,5-dimethyl-1h-imidazol-2-yl)phenyl]-3-(oxan-4-ylmethyl)-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound N1C(C)=C(C)N=C1C1=CC=C(C=2N=C3N(CC4CCOCC4)C(=O)NC3=NC=2)C=C1 FDOGTFDCNZSVTD-UHFFFAOYSA-N 0.000 description 1
• HVUORIHKFKVNQF-UHFFFAOYSA-N 5-[4-(5-methyl-1h-1,2,4-triazol-3-yl)phenyl]-3-[2-(oxan-4-yl)ethyl]-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound N1C(C)=NC(C=2C=CC(=CC=2)C=2N=C3N(CCC4CCOCC4)C(=O)NC3=NC=2)=N1 HVUORIHKFKVNQF-UHFFFAOYSA-N 0.000 description 1
• UMRHEAFJGPOZGL-UHFFFAOYSA-N 5-[4-(aminomethyl)phenyl]-3-(cyclohexylmethyl)-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound C1=CC(CN)=CC=C1C1=CN=C(NC(=O)N2CC3CCCCC3)C2=N1 UMRHEAFJGPOZGL-UHFFFAOYSA-N 0.000 description 1
• ABIYZEMGQIMMFY-UHFFFAOYSA-N 5-[4-(hydroxymethyl)thiophen-2-yl]-3-(oxan-4-ylmethyl)-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound OCC1=CSC(C=2N=C3N(CC4CCOCC4)C(=O)NC3=NC=2)=C1 ABIYZEMGQIMMFY-UHFFFAOYSA-N 0.000 description 1
• ZIFHJWSXCVZLDX-UHFFFAOYSA-N 5-[4-[5-(methylaminomethyl)-1h-1,2,4-triazol-3-yl]phenyl]-3-(oxan-4-ylmethyl)-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound N1C(CNC)=NC(C=2C=CC(=CC=2)C=2N=C3N(CC4CCOCC4)C(=O)NC3=NC=2)=N1 ZIFHJWSXCVZLDX-UHFFFAOYSA-N 0.000 description 1
• SZMOTAFHAMLZDP-UHFFFAOYSA-N 5-[5-(2-hydroxyethyl)thiophen-2-yl]-3-(oxan-4-ylmethyl)-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound S1C(CCO)=CC=C1C1=CN=C(NC(=O)N2CC3CCOCC3)C2=N1 SZMOTAFHAMLZDP-UHFFFAOYSA-N 0.000 description 1
• PLWDQSKPAOOXAW-UHFFFAOYSA-N 5-[5-(hydroxymethyl)thiophen-2-yl]-3-(oxan-4-ylmethyl)-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound S1C(CO)=CC=C1C1=CN=C(NC(=O)N2CC3CCOCC3)C2=N1 PLWDQSKPAOOXAW-UHFFFAOYSA-N 0.000 description 1
• ONDJQRZDLSDOJA-UHFFFAOYSA-N 5-[6-(2-hydroxypropan-2-yl)pyridin-3-yl]-3-[2-(oxan-4-yl)ethyl]-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound C1=NC(C(C)(O)C)=CC=C1C1=CN=C(NC(=O)N2CCC3CCOCC3)C2=N1 ONDJQRZDLSDOJA-UHFFFAOYSA-N 0.000 description 1
• FPOJUEVZPINGBY-UHFFFAOYSA-N 5-[6-(methylamino)pyridin-3-yl]-3-(oxan-4-ylmethyl)-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound C1=NC(NC)=CC=C1C1=CN=C(NC(=O)N2CC3CCOCC3)C2=N1 FPOJUEVZPINGBY-UHFFFAOYSA-N 0.000 description 1
• WYLXUTPYMYKVJF-UHFFFAOYSA-N 5-ethyl-3-(1h-indazol-4-yl)-7,8-dihydropyrazino[2,3-b]pyrazin-6-one Chemical compound N1=C2N(CC)C(=O)CNC2=NC=C1C1=CC=CC2=C1C=NN2 WYLXUTPYMYKVJF-UHFFFAOYSA-N 0.000 description 1
• ZZQICLYBVODNQP-UHFFFAOYSA-N 5-ethyl-3-[5-fluoro-2-methyl-4-(1h-1,2,4-triazol-5-yl)phenyl]-7,8-dihydropyrazino[2,3-b]pyrazin-6-one Chemical compound N1=C2N(CC)C(=O)CNC2=NC=C1C(C(=C1)C)=CC(F)=C1C=1N=CNN=1 ZZQICLYBVODNQP-UHFFFAOYSA-N 0.000 description 1
• XEPYGEAUHALMSW-UHFFFAOYSA-N 5-isoquinolin-5-yl-3-(1-phenylethyl)-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound C12=NC(C=3C4=CC=NC=C4C=CC=3)=CN=C2NC(=O)N1C(C)C1=CC=CC=C1 XEPYGEAUHALMSW-UHFFFAOYSA-N 0.000 description 1
• HMOJZFVMIKFVAQ-UHFFFAOYSA-N 5-phenyl-1,3-dihydroimidazo[4,5-b]pyrazin-2-one Chemical compound N1=C2NC(=O)NC2=NC=C1C1=CC=CC=C1 HMOJZFVMIKFVAQ-UHFFFAOYSA-N 0.000 description 1
• PIZRDBDKCZOJFX-UHFFFAOYSA-N 5-quinolin-5-yl-1,3-dihydroimidazo[4,5-b]pyrazin-2-one Chemical compound C1=CC=C2C(C3=CN=C4NC(NC4=N3)=O)=CC=CC2=N1 PIZRDBDKCZOJFX-UHFFFAOYSA-N 0.000 description 1
• CWDFAIOBIJKAGT-UHFFFAOYSA-N 6-[1-[2-(oxan-4-yl)ethyl]-2H-pyrazin-5-yl]-1H-indazole Chemical compound N1N=CC2=CC=C(C=C12)C1=CN(CC=N1)CCC1CCOCC1 CWDFAIOBIJKAGT-UHFFFAOYSA-N 0.000 description 1
• RHCAZYILHJYUKB-STUHELBRSA-N 6-[[(3s,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]amino]-1h-pyrimidin-2-one Chemical compound O[C@H]1[C@H](O)[C@@H](CO)OC1NC1=CC=NC(=O)N1 RHCAZYILHJYUKB-STUHELBRSA-N 0.000 description 1
• LJIRBXZDQGQUOO-KVTDHHQDSA-N 6-amino-3-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,4-dihydro-1,3,5-triazin-2-one Chemical compound C1NC(N)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 LJIRBXZDQGQUOO-KVTDHHQDSA-N 0.000 description 1
• WVZMHVPOOSNVDH-UHFFFAOYSA-N 6-pyridin-4-yl-1,3-dihydroimidazo[4,5-b]pyridin-2-one Chemical compound C=1N=C2NC(=O)NC2=CC=1C1=CC=NC=C1 WVZMHVPOOSNVDH-UHFFFAOYSA-N 0.000 description 1
• ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
• PBUPUHCPBXBSKQ-UHFFFAOYSA-N 8-oxo-9-(2-propan-2-ylphenyl)-2-[4-(2h-triazol-4-yl)phenyl]-7h-purine-6-carboxamide Chemical compound CC(C)C1=CC=CC=C1N1C(=O)NC2=C(C(N)=O)N=C(C=3C=CC(=CC=3)C=3NN=NC=3)N=C21 PBUPUHCPBXBSKQ-UHFFFAOYSA-N 0.000 description 1
• WJYJGGLXBRMCTQ-UHFFFAOYSA-N 8-phenyl-2-pyridin-3-yl-7H-purine-6-carboxamide Chemical compound C1(=CC=CC=C1)C1=NC2=NC(=NC(=C2N1)C(=O)N)C=1C=NC=CC=1 WJYJGGLXBRMCTQ-UHFFFAOYSA-N 0.000 description 1
• YHAKLGLSQXIZCK-UHFFFAOYSA-N 9-(2-methoxyphenyl)-2-(2-methyl-3h-benzimidazol-5-yl)-8-oxo-7h-purine-6-carboxamide Chemical compound COC1=CC=CC=C1N1C(=O)NC2=C(C(N)=O)N=C(C=3C=C4NC(C)=NC4=CC=3)N=C21 YHAKLGLSQXIZCK-UHFFFAOYSA-N 0.000 description 1
• AGLIYPCDJKUNQG-UHFFFAOYSA-N 9-(2-methoxyphenyl)-8-oxo-2-pyridin-4-yl-7h-purine-6-carboxamide Chemical compound COC1=CC=CC=C1N1C(=O)NC2=C(C(N)=O)N=C(C=3C=CN=CC=3)N=C21 AGLIYPCDJKUNQG-UHFFFAOYSA-N 0.000 description 1
• DKWQALXHTVXPHP-UHFFFAOYSA-N 9-methyl-8-oxo-2-pyridin-3-yl-7h-purine-6-carboxamide Chemical compound N=1C(C(N)=O)=C2NC(=O)N(C)C2=NC=1C1=CC=CN=C1 DKWQALXHTVXPHP-UHFFFAOYSA-N 0.000 description 1
• AENLBSGSASHWDU-UHFFFAOYSA-N 9-phenyl-2-pyridin-3-ylpurine-6-carboxamide Chemical compound C1=NC=2C(C(=O)N)=NC(C=3C=NC=CC=3)=NC=2N1C1=CC=CC=C1 AENLBSGSASHWDU-UHFFFAOYSA-N 0.000 description 1
• 244000215068 Acacia senegal Species 0.000 description 1
• 208000031261 Acute myeloid leukaemia Diseases 0.000 description 1
• 229920001817 Agar Polymers 0.000 description 1
• 229940126638 Akt inhibitor Drugs 0.000 description 1
• WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 description 1
• 239000005995 Aluminium silicate Substances 0.000 description 1
• QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 1
• 101100496169 Arabidopsis thaliana CLH1 gene Proteins 0.000 description 1
• 206010003571 Astrocytoma Diseases 0.000 description 1
• 201000001320 Atherosclerosis Diseases 0.000 description 1
• 229920003084 Avicel® PH-102 Polymers 0.000 description 1
• 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 1
• 206010057393 Bifascicular block Diseases 0.000 description 1
• 241000283690 Bos taurus Species 0.000 description 1
• COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
• KVJJVRBDALETMO-UHFFFAOYSA-N C1(=CC=CC=C1)C(C)N1COC(=C1)C1=C2C=CC=NC2=CC=C1 Chemical compound C1(=CC=CC=C1)C(C)N1COC(=C1)C1=C2C=CC=NC2=CC=C1 KVJJVRBDALETMO-UHFFFAOYSA-N 0.000 description 1
• ZLNBWRIUBYDYQS-BJHJDKERSA-N C1C[C@@H](COC)CC[C@H]1N1C(=O)NC2=C(C(N)=O)N=C(C=3C=C(O)C=CC=3)N=C21 Chemical compound C1C[C@@H](COC)CC[C@H]1N1C(=O)NC2=C(C(N)=O)N=C(C=3C=C(O)C=CC=3)N=C21 ZLNBWRIUBYDYQS-BJHJDKERSA-N 0.000 description 1
• BQWNQORJQWSVMS-QAQDUYKDSA-N C1C[C@@H](OC)CC[C@@H]1N1C2=NC(C=3C=CC(=CC=3)C(C)(C)O)=CN=C2NCC1=O Chemical compound C1C[C@@H](OC)CC[C@@H]1N1C2=NC(C=3C=CC(=CC=3)C(C)(C)O)=CN=C2NCC1=O BQWNQORJQWSVMS-QAQDUYKDSA-N 0.000 description 1
• OACQOYQOCHYLIO-TXEJJXNPSA-N C1C[C@@H](OC)CC[C@H]1N1C(=O)NC2=C(C(N)=O)N=C(C=3C=C4NC=NC4=CC=3)N=C21 Chemical compound C1C[C@@H](OC)CC[C@H]1N1C(=O)NC2=C(C(N)=O)N=C(C=3C=C4NC=NC4=CC=3)N=C21 OACQOYQOCHYLIO-TXEJJXNPSA-N 0.000 description 1
• PJTRKGQWHOCYFU-UHFFFAOYSA-N CC(C)C1=CC=CC(=C1)C2=CN=C3C(=N2)N(C=N3)C(C)C Chemical compound CC(C)C1=CC=CC(=C1)C2=CN=C3C(=N2)N(C=N3)C(C)C PJTRKGQWHOCYFU-UHFFFAOYSA-N 0.000 description 1
• JGLMVXWAHNTPRF-CMDGGOBGSA-N CCN1N=C(C)C=C1C(=O)NC1=NC2=CC(=CC(OC)=C2N1C\C=C\CN1C(NC(=O)C2=CC(C)=NN2CC)=NC2=CC(=CC(OCCCN3CCOCC3)=C12)C(N)=O)C(N)=O Chemical compound CCN1N=C(C)C=C1C(=O)NC1=NC2=CC(=CC(OC)=C2N1C\C=C\CN1C(NC(=O)C2=CC(C)=NN2CC)=NC2=CC(=CC(OCCCN3CCOCC3)=C12)C(N)=O)C(N)=O JGLMVXWAHNTPRF-CMDGGOBGSA-N 0.000 description 1
• NFGFDQVRGRYAKJ-GASCZTMLSA-N CO[C@H]1CC[C@H](CC1)N1CC=NC(=C1)C=1C(=NC(=CC=1)C1=NN=CN1)C Chemical compound CO[C@H]1CC[C@H](CC1)N1CC=NC(=C1)C=1C(=NC(=CC=1)C1=NN=CN1)C NFGFDQVRGRYAKJ-GASCZTMLSA-N 0.000 description 1
• GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 description 1
• GAGWJHPBXLXJQN-UHFFFAOYSA-N Capecitabine Natural products C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1C1C(O)C(O)C(C)O1 GAGWJHPBXLXJQN-UHFFFAOYSA-N 0.000 description 1
• OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
• 239000004215 Carbon black (E152) Substances 0.000 description 1
• OKTJSMMVPCPJKN-NJFSPNSNSA-N Carbon-14 Chemical compound [14C] OKTJSMMVPCPJKN-NJFSPNSNSA-N 0.000 description 1
• 241000700199 Cavia porcellus Species 0.000 description 1
• 101150015280 Cel gene Proteins 0.000 description 1
• 238000003734 CellTiter-Glo Luminescent Cell Viability Assay Methods 0.000 description 1
• 241000282693 Cercopithecidae Species 0.000 description 1
• GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 1
• 208000000419 Chronic Hepatitis B Diseases 0.000 description 1
• 208000000668 Chronic Pancreatitis Diseases 0.000 description 1
• 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 1
• 241000207199 Citrus Species 0.000 description 1
• ZUCJXDMAMYYVEV-UHFFFAOYSA-N Cl.CC1=NC2=C(N1)C=CC(=C2)C2=CN=C1C(=N2)N(C=N1)CC1CCOCC1 Chemical compound Cl.CC1=NC2=C(N1)C=CC(=C2)C2=CN=C1C(=N2)N(C=N1)CC1CCOCC1 ZUCJXDMAMYYVEV-UHFFFAOYSA-N 0.000 description 1
• 229920002261 Corn starch Polymers 0.000 description 1
• 240000009087 Crescentia cujete Species 0.000 description 1
• 235000005983 Crescentia cujete Nutrition 0.000 description 1
• 108090000695 Cytokines Proteins 0.000 description 1
• 102000004127 Cytokines Human genes 0.000 description 1
• FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
• FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
• NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 1
• FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
• 206010012735 Diarrhoea Diseases 0.000 description 1
• 208000002699 Digestive System Neoplasms Diseases 0.000 description 1
• 206010059866 Drug resistance Diseases 0.000 description 1
• 102000001301 EGF receptor Human genes 0.000 description 1
• 108060006698 EGF receptor Proteins 0.000 description 1
• 101150039808 Egfr gene Proteins 0.000 description 1
• FLFGNMFWNBOBGE-FNNZEKJRSA-N Elacytarabine Chemical compound O[C@H]1[C@H](O)[C@@H](COC(=O)CCCCCCC/C=C/CCCCCCCC)O[C@H]1N1C(=O)N=C(N)C=C1 FLFGNMFWNBOBGE-FNNZEKJRSA-N 0.000 description 1
• XQSPYNMVSIKCOC-NTSWFWBYSA-N Emtricitabine Chemical compound C1=C(F)C(N)=NC(=O)N1[C@H]1O[C@@H](CO)SC1 XQSPYNMVSIKCOC-NTSWFWBYSA-N 0.000 description 1
• 241000283073 Equus caballus Species 0.000 description 1
• VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
• 239000001856 Ethyl cellulose Substances 0.000 description 1
• ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
• 239000005977 Ethylene Substances 0.000 description 1
• PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
• ZLQNFAHANKTJSH-GASCZTMLSA-N FC=1C(=C(C=CC=1C1=NNC=N1)C1=CN(CC=N1)[C@@H]1CC[C@@H](CC1)OC)C Chemical compound FC=1C(=C(C=CC=1C1=NNC=N1)C1=CN(CC=N1)[C@@H]1CC[C@@H](CC1)OC)C ZLQNFAHANKTJSH-GASCZTMLSA-N 0.000 description 1
• ZBDNHKJIWFDGKS-SHTZXODSSA-N FC=1C(=CC(=C(C=1)C1=CN(CC=N1)C[C@@H]1CC[C@H](CC1)O)C)C1=NNC=N1 Chemical compound FC=1C(=CC(=C(C=1)C1=CN(CC=N1)C[C@@H]1CC[C@H](CC1)O)C)C1=NNC=N1 ZBDNHKJIWFDGKS-SHTZXODSSA-N 0.000 description 1
• MLPANBSYVGMHEV-WKILWMFISA-N FC=1C(=CC(=C(C=1)C1=CN(CC=N1)C[C@@H]1CC[C@H](CC1)OC)C)C1=NNC=N1 Chemical compound FC=1C(=CC(=C(C=1)C1=CN(CC=N1)C[C@@H]1CC[C@H](CC1)OC)C)C1=NNC=N1 MLPANBSYVGMHEV-WKILWMFISA-N 0.000 description 1
• QPSJNZGTINPISD-HDJSIYSDSA-N FC=1C(=CC(=C(C=1)C1=CN(CC=N1)[C@@H]1CC[C@H](CC1)O)C)C1=NNC=N1 Chemical compound FC=1C(=CC(=C(C=1)C1=CN(CC=N1)[C@@H]1CC[C@H](CC1)O)C)C1=NNC=N1 QPSJNZGTINPISD-HDJSIYSDSA-N 0.000 description 1
• VCEXKZSWJKQUTJ-SHTZXODSSA-N FC=1C(=CC(=C(C=1)C1=CN(CC=N1)[C@@H]1CC[C@H](CC1)OC)C)C1=NNC=N1 Chemical compound FC=1C(=CC(=C(C=1)C1=CN(CC=N1)[C@@H]1CC[C@H](CC1)OC)C)C1=NNC=N1 VCEXKZSWJKQUTJ-SHTZXODSSA-N 0.000 description 1
• 241000282326 Felis catus Species 0.000 description 1
• 241000287828 Gallus gallus Species 0.000 description 1
• 239000004471 Glycine Substances 0.000 description 1
• 229920002907 Guar gum Polymers 0.000 description 1
• 229920000084 Gum arabic Polymers 0.000 description 1
• 239000007995 HEPES buffer Substances 0.000 description 1
• 102000001554 Hemoglobins Human genes 0.000 description 1
• 108010054147 Hemoglobins Proteins 0.000 description 1
• 206010019695 Hepatic neoplasm Diseases 0.000 description 1
• 241000725303 Human immunodeficiency virus Species 0.000 description 1
• 206010020772 Hypertension Diseases 0.000 description 1
• DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
• 206010023439 Kidney transplant rejection Diseases 0.000 description 1
• 125000002066 L-histidyl group Chemical group [H]N1C([H])=NC(C([H])([H])[C@](C(=O)[*])([H])N([H])[H])=C1[H] 0.000 description 1
• KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
• 125000002842 L-seryl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])O[H] 0.000 description 1
• 240000007472 Leucaena leucocephala Species 0.000 description 1
• 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
• WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
• 239000004472 Lysine Substances 0.000 description 1
• KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
• 206010025476 Malabsorption Diseases 0.000 description 1
• 208000004155 Malabsorption Syndromes Diseases 0.000 description 1
• 229910021380 Manganese Chloride Inorganic materials 0.000 description 1
• GLFNIEUTAYBVOC-UHFFFAOYSA-L Manganese chloride Chemical compound Cl[Mn]Cl GLFNIEUTAYBVOC-UHFFFAOYSA-L 0.000 description 1
• 101100044057 Mesocricetus auratus SYCP3 gene Proteins 0.000 description 1
• 206010027476 Metastases Diseases 0.000 description 1
• 241000699660 Mus musculus Species 0.000 description 1
• 201000003793 Myelodysplastic syndrome Diseases 0.000 description 1
• 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 1
• 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 1
• HSHXDCVZWHOWCS-UHFFFAOYSA-N N'-hexadecylthiophene-2-carbohydrazide Chemical compound CCCCCCCCCCCCCCCCNNC(=O)c1cccs1 HSHXDCVZWHOWCS-UHFFFAOYSA-N 0.000 description 1
• JPPUYLZFFQOKOJ-UHFFFAOYSA-N N,4-dimethyl-6-[1-[2-(oxan-4-yl)ethyl]-2H-pyrazin-5-yl]-1H-benzimidazol-2-amine Chemical compound CC1=CC(=CC=2NC(=NC=21)NC)C1=CN(CC=N1)CCC1CCOCC1 JPPUYLZFFQOKOJ-UHFFFAOYSA-N 0.000 description 1
• CFDAMSKFBGKPER-FZNQNYSPSA-N N1N=C(N=C1)C1=CC=C(C=N1)C1=CN(CC=N1)C[C@@H]1CC[C@@H](CC1)OC Chemical compound N1N=C(N=C1)C1=CC=C(C=N1)C1=CN(CC=N1)C[C@@H]1CC[C@@H](CC1)OC CFDAMSKFBGKPER-FZNQNYSPSA-N 0.000 description 1
• GKWUIGQZEWIYFT-HDJSIYSDSA-N N1N=C(N=C1)C1=CC=C(C=N1)C1=CN(CC=N1)[C@@H]1CC[C@H](CC1)O Chemical compound N1N=C(N=C1)C1=CC=C(C=N1)C1=CN(CC=N1)[C@@H]1CC[C@H](CC1)O GKWUIGQZEWIYFT-HDJSIYSDSA-N 0.000 description 1
• RVTVJCBZKCZEQU-UHFFFAOYSA-N NC=1NC2=C(N1)C=CC(=C2)C2CCCCC2CN2CNC=C2 Chemical compound NC=1NC2=C(N1)C=CC(=C2)C2CCCCC2CN2CNC=C2 RVTVJCBZKCZEQU-UHFFFAOYSA-N 0.000 description 1
• 102000007399 Nuclear hormone receptor Human genes 0.000 description 1
• 108020005497 Nuclear hormone receptor Proteins 0.000 description 1
• SBTDRJLUYFJUKT-RUCARUNLSA-N OC(C)(C)C1=CC=C(C=C1)C1=CN(CC=N1)C[C@@H]1CC[C@H](CC1)OC Chemical compound OC(C)(C)C1=CC=C(C=C1)C1=CN(CC=N1)C[C@@H]1CC[C@H](CC1)OC SBTDRJLUYFJUKT-RUCARUNLSA-N 0.000 description 1
• QUWKVCJHXYZIOX-JCNLHEQBSA-N OC(C)(C)C1=CC=C(C=N1)C1=CN(CC=N1)C[C@@H]1CC[C@H](CC1)OC Chemical compound OC(C)(C)C1=CC=C(C=N1)C1=CN(CC=N1)C[C@@H]1CC[C@H](CC1)OC QUWKVCJHXYZIOX-JCNLHEQBSA-N 0.000 description 1
• CPQNTOFOBBARCH-IYBDPMFKSA-N OC(C)(C)C1=CC=C(C=N1)C1=CN(CC=N1)[C@@H]1CC[C@@H](CC1)OC Chemical compound OC(C)(C)C1=CC=C(C=N1)C1=CN(CC=N1)[C@@H]1CC[C@@H](CC1)OC CPQNTOFOBBARCH-IYBDPMFKSA-N 0.000 description 1
• CPQNTOFOBBARCH-WKILWMFISA-N OC(C)(C)C1=CC=C(C=N1)C1=CN(CC=N1)[C@@H]1CC[C@H](CC1)OC Chemical compound OC(C)(C)C1=CC=C(C=N1)C1=CN(CC=N1)[C@@H]1CC[C@H](CC1)OC CPQNTOFOBBARCH-WKILWMFISA-N 0.000 description 1
• IQPZOVAOFOKTPD-UHFFFAOYSA-N OC1=CC=C(C=C1)C1=CN=C2C(=N1)N(C(N2)=O)C(C)C2=CC=CC=C2 Chemical compound OC1=CC=C(C=C1)C1=CN=C2C(=N1)N(C(N2)=O)C(C)C2=CC=CC=C2 IQPZOVAOFOKTPD-UHFFFAOYSA-N 0.000 description 1
• UPBMCMHHAALSFQ-SHTZXODSSA-N O[C@@H]1CC[C@H](CC1)N1CC=NC(=C1)C=1C=NC(=CC=1)C(C)(C)O Chemical compound O[C@@H]1CC[C@H](CC1)N1CC=NC(=C1)C=1C=NC(=CC=1)C(C)(C)O UPBMCMHHAALSFQ-SHTZXODSSA-N 0.000 description 1
• UPBMCMHHAALSFQ-GASCZTMLSA-N O[C@H]1CC[C@H](CC1)N1CC=NC(=C1)C=1C=NC(=CC=1)C(C)(C)O Chemical compound O[C@H]1CC[C@H](CC1)N1CC=NC(=C1)C=1C=NC(=CC=1)C(C)(C)O UPBMCMHHAALSFQ-GASCZTMLSA-N 0.000 description 1
• 208000008589 Obesity Diseases 0.000 description 1
• 108700020796 Oncogene Proteins 0.000 description 1
• 102000043276 Oncogene Human genes 0.000 description 1
• 241000283973 Oryctolagus cuniculus Species 0.000 description 1
• 239000012828 PI3K inhibitor Substances 0.000 description 1
• 229930012538 Paclitaxel Natural products 0.000 description 1
• 206010033645 Pancreatitis Diseases 0.000 description 1
• 206010033647 Pancreatitis acute Diseases 0.000 description 1
• 206010033649 Pancreatitis chronic Diseases 0.000 description 1
• 241001494479 Pecora Species 0.000 description 1
• 241000009328 Perro Species 0.000 description 1
• 240000009164 Petroselinum crispum Species 0.000 description 1
• 241000286209 Phasianidae Species 0.000 description 1
• 229920001213 Polysorbate 20 Polymers 0.000 description 1
• 239000004793 Polystyrene Substances 0.000 description 1
• 108700020978 Proto-Oncogene Proteins 0.000 description 1
• 102000052575 Proto-Oncogene Human genes 0.000 description 1
• 241000700159 Rattus Species 0.000 description 1
• 230000018199 S phase Effects 0.000 description 1
• 101100080600 Schizosaccharomyces pombe (strain 972 / ATCC 24843) nse6 gene Proteins 0.000 description 1
• 102100023085 Serine/threonine-protein kinase mTOR Human genes 0.000 description 1
• 241000384008 Sisis Species 0.000 description 1
• DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
• 239000004141 Sodium laurylsulphate Substances 0.000 description 1
• 235000021355 Stearic acid Nutrition 0.000 description 1
• QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
• 241000282898 Sus scrofa Species 0.000 description 1
• 210000001744 T-lymphocyte Anatomy 0.000 description 1
• FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
• 239000007983 Tris buffer Substances 0.000 description 1
• YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
• 239000013504 Triton X-100 Substances 0.000 description 1
• 229920004890 Triton X-100 Polymers 0.000 description 1
• 102000044209 Tumor Suppressor Genes Human genes 0.000 description 1
• 108700025716 Tumor Suppressor Genes Proteins 0.000 description 1
• 102000001742 Tumor Suppressor Proteins Human genes 0.000 description 1
• 108010040002 Tumor Suppressor Proteins Proteins 0.000 description 1
• 208000007814 Unstable Angina Diseases 0.000 description 1
• 229940127538 Vascular Endothelial Growth Factor Receptor Inhibitors Drugs 0.000 description 1
• 206010047281 Ventricular arrhythmia Diseases 0.000 description 1
• 208000036142 Viral infection Diseases 0.000 description 1
• 240000008042 Zea mays Species 0.000 description 1
• 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
• 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
• HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
• AYVGBNGTBQLJBG-UHFFFAOYSA-N [3-(hydroxymethyl)cyclopentyl]methanol Chemical compound OCC1CCC(CO)C1 AYVGBNGTBQLJBG-UHFFFAOYSA-N 0.000 description 1
• 235000010489 acacia gum Nutrition 0.000 description 1
• 239000000205 acacia gum Substances 0.000 description 1
• 125000000738 acetamido group Chemical group [H]C([H])([H])C(=O)N([H])[*] 0.000 description 1
• 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
• 125000000641 acridinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3C=C12)* 0.000 description 1
• 239000008186 active pharmaceutical agent Substances 0.000 description 1
• 239000013543 active substance Substances 0.000 description 1
• 201000003229 acute pancreatitis Diseases 0.000 description 1
• 125000002015 acyclic group Chemical group 0.000 description 1
• 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 description 1
• 208000009956 adenocarcinoma Diseases 0.000 description 1
• 230000002411 adverse Effects 0.000 description 1
• 239000008272 agar Substances 0.000 description 1
• 235000010419 agar Nutrition 0.000 description 1
• 239000000783 alginic acid Substances 0.000 description 1
• 229960001126 alginic acid Drugs 0.000 description 1
• 150000004781 alginic acids Chemical class 0.000 description 1
• 125000001931 aliphatic group Chemical group 0.000 description 1
• 125000005907 alkyl ester group Chemical group 0.000 description 1
• 125000004656 alkyl sulfonylamino group Chemical group 0.000 description 1
• 229910052782 aluminium Inorganic materials 0.000 description 1
• XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
• 235000012211 aluminium silicate Nutrition 0.000 description 1
• CEGOLXSVJUTHNZ-UHFFFAOYSA-K aluminium tristearate Chemical compound [Al+3].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CEGOLXSVJUTHNZ-UHFFFAOYSA-K 0.000 description 1
• 229940063655 aluminum stearate Drugs 0.000 description 1
• 150000001408 amides Chemical class 0.000 description 1
• BBDAGFIXKZCXAH-CCXZUQQUSA-N ancitabine Chemical compound N=C1C=CN2[C@@H]3O[C@H](CO)[C@@H](O)[C@@H]3OC2=N1 BBDAGFIXKZCXAH-CCXZUQQUSA-N 0.000 description 1
• 230000008485 antagonism Effects 0.000 description 1
• 125000005427 anthranyl group Chemical group 0.000 description 1
• 125000005428 anthryl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C3C(*)=C([H])C([H])=C([H])C3=C([H])C2=C1[H] 0.000 description 1
• 230000006907 apoptotic process Effects 0.000 description 1
• 235000015197 apple juice Nutrition 0.000 description 1
• METKIMKYRPQLGS-UHFFFAOYSA-N atenolol Chemical compound CC(C)NCC(O)COC1=CC=C(CC(N)=O)C=C1 METKIMKYRPQLGS-UHFFFAOYSA-N 0.000 description 1
• 229940039845 azacitidine 100 mg Drugs 0.000 description 1
• 125000002393 azetidinyl group Chemical group 0.000 description 1
• 125000004069 aziridinyl group Chemical group 0.000 description 1
• 210000003719 b-lymphocyte Anatomy 0.000 description 1
• 230000009286 beneficial effect Effects 0.000 description 1
• 230000008901 benefit Effects 0.000 description 1
• 239000000440 bentonite Substances 0.000 description 1
• 229910000278 bentonite Inorganic materials 0.000 description 1
• 235000012216 bentonite Nutrition 0.000 description 1
• SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
• JUHORIMYRDESRB-UHFFFAOYSA-N benzathine Chemical compound C=1C=CC=CC=1CNCCNCC1=CC=CC=C1 JUHORIMYRDESRB-UHFFFAOYSA-N 0.000 description 1
• 125000005605 benzo group Chemical group 0.000 description 1
• 125000004622 benzoxazinyl group Chemical group O1NC(=CC2=C1C=CC=C2)* 0.000 description 1
• 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
• 125000002619 bicyclic group Chemical group 0.000 description 1
• 238000010876 biochemical test Methods 0.000 description 1
• 230000004071 biological effect Effects 0.000 description 1
• 230000033228 biological regulation Effects 0.000 description 1
• 239000012472 biological sample Substances 0.000 description 1
• 230000015572 biosynthetic process Effects 0.000 description 1
• 125000006269 biphenyl-2-yl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C1=C(*)C([H])=C([H])C([H])=C1[H] 0.000 description 1
• 210000000601 blood cell Anatomy 0.000 description 1
• 230000036772 blood pressure Effects 0.000 description 1
• 239000007853 buffer solution Substances 0.000 description 1
• 229910000019 calcium carbonate Inorganic materials 0.000 description 1
• 235000010216 calcium carbonate Nutrition 0.000 description 1
• FNAQSUUGMSOBHW-UHFFFAOYSA-H calcium citrate Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O FNAQSUUGMSOBHW-UHFFFAOYSA-H 0.000 description 1
• 239000001354 calcium citrate Substances 0.000 description 1
• CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
• 235000013539 calcium stearate Nutrition 0.000 description 1
• 239000008116 calcium stearate Substances 0.000 description 1
• OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Inorganic materials [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 1
• 238000004364 calculation method Methods 0.000 description 1
• 229960004117 capecitabine Drugs 0.000 description 1
• 150000004657 carbamic acid derivatives Chemical class 0.000 description 1
• 125000002837 carbocyclic group Chemical group 0.000 description 1
• 150000001722 carbon compounds Chemical class 0.000 description 1
• 239000011203 carbon fibre reinforced carbon Substances 0.000 description 1
• 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
• 239000001768 carboxy methyl cellulose Substances 0.000 description 1
• 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
• 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
• 239000000969 carrier Substances 0.000 description 1
• 239000003729 cation exchange resin Substances 0.000 description 1
• 229940023913 cation exchange resins Drugs 0.000 description 1
• 230000021164 cell adhesion Effects 0.000 description 1
• 230000025084 cell cycle arrest Effects 0.000 description 1
• 230000006369 cell cycle progression Effects 0.000 description 1
• 230000024245 cell differentiation Effects 0.000 description 1
• 230000003915 cell function Effects 0.000 description 1
• 239000013592 cell lysate Substances 0.000 description 1
• 238000001516 cell proliferation assay Methods 0.000 description 1
• 238000003570 cell viability assay Methods 0.000 description 1
• 235000013339 cereals Nutrition 0.000 description 1
• HNDNYBMXRPPOJM-UHFFFAOYSA-N chembl1945787 Chemical compound C=1N=C2NC(=O)N(CCOC)C2=NC=1C1=CC=C(O)C=C1 HNDNYBMXRPPOJM-UHFFFAOYSA-N 0.000 description 1
• FMIYVWZLZNGVQL-UHFFFAOYSA-N chembl1945788 Chemical compound C=1N=C2NC(=O)N(CC(C)C)C2=NC=1C1=CC=C(O)C=C1 FMIYVWZLZNGVQL-UHFFFAOYSA-N 0.000 description 1
• WZORNRLHVWJBIW-UHFFFAOYSA-N chembl1945791 Chemical compound C1=CC(O)=CC=C1C1=CN=C(NC(=O)N2C3CCCCC3)C2=N1 WZORNRLHVWJBIW-UHFFFAOYSA-N 0.000 description 1
• 230000002113 chemopreventative effect Effects 0.000 description 1
• VDANGULDQQJODZ-UHFFFAOYSA-N chloroprocaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1Cl VDANGULDQQJODZ-UHFFFAOYSA-N 0.000 description 1
• 229960002023 chloroprocaine Drugs 0.000 description 1
• OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
• 229960001231 choline Drugs 0.000 description 1
• 230000001684 chronic effect Effects 0.000 description 1
• 208000037976 chronic inflammation Diseases 0.000 description 1
• 208000037893 chronic inflammatory disorder Diseases 0.000 description 1
• 235000020971 citrus fruits Nutrition 0.000 description 1
• 229940000425 combination drug Drugs 0.000 description 1
• 229940126543 compound 14 Drugs 0.000 description 1
• 229940126086 compound 21 Drugs 0.000 description 1
• 238000007796 conventional method Methods 0.000 description 1
• 101150111293 cor-1 gene Proteins 0.000 description 1
• 235000005822 corn Nutrition 0.000 description 1
• 230000002596 correlated effect Effects 0.000 description 1
• 229940109239 creatinine Drugs 0.000 description 1
• 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
• 108010073357 cyanoginosin LR Proteins 0.000 description 1
• WZHCOOQXZCIUNC-UHFFFAOYSA-N cyclandelate Chemical compound C1C(C)(C)CC(C)CC1OC(=O)C(O)C1=CC=CC=C1 WZHCOOQXZCIUNC-UHFFFAOYSA-N 0.000 description 1
• 125000006165 cyclic alkyl group Chemical group 0.000 description 1
• 125000004367 cycloalkylaryl group Chemical group 0.000 description 1
• 125000003678 cyclohexadienyl group Chemical group C1(=CC=CCC1)* 0.000 description 1
• 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 1
• 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
• 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 1
• 229940059359 dacogen Drugs 0.000 description 1
• 229960003603 decitabine Drugs 0.000 description 1
• 230000001934 delay Effects 0.000 description 1
• 238000013461 design Methods 0.000 description 1
• 238000003745 diagnosis Methods 0.000 description 1
• 239000000032 diagnostic agent Substances 0.000 description 1
• 229940039227 diagnostic agent Drugs 0.000 description 1
• 235000014113 dietary fatty acids Nutrition 0.000 description 1
• 235000020805 dietary restrictions Nutrition 0.000 description 1
• ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
• 229940043237 diethanolamine Drugs 0.000 description 1
• 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 1
• 238000007907 direct compression Methods 0.000 description 1
• 239000002270 dispersing agent Substances 0.000 description 1
• 231100000371 dose-limiting toxicity Toxicity 0.000 description 1
• 239000000890 drug combination Substances 0.000 description 1
• 238000007876 drug discovery Methods 0.000 description 1
• 239000003596 drug target Substances 0.000 description 1
• 238000007908 dry granulation Methods 0.000 description 1
• 229940096118 ella Drugs 0.000 description 1
• 229940001018 emtriva Drugs 0.000 description 1
• 108700021358 erbB-1 Genes Proteins 0.000 description 1
• 230000032050 esterification Effects 0.000 description 1
• 238000005886 esterification reaction Methods 0.000 description 1
• 235000019325 ethyl cellulose Nutrition 0.000 description 1
• 229920001249 ethyl cellulose Polymers 0.000 description 1
• 229940012017 ethylenediamine Drugs 0.000 description 1
• 230000005284 excitation Effects 0.000 description 1
• 230000007717 exclusion Effects 0.000 description 1
• 238000002474 experimental method Methods 0.000 description 1
• 208000015700 familial long QT syndrome Diseases 0.000 description 1
• 239000000194 fatty acid Substances 0.000 description 1
• 229930195729 fatty acid Natural products 0.000 description 1
• 150000004665 fatty acids Chemical class 0.000 description 1
• 230000002349 favourable effect Effects 0.000 description 1
• 229950005096 fazarabine Drugs 0.000 description 1
• 238000013100 final test Methods 0.000 description 1
• 239000000796 flavoring agent Substances 0.000 description 1
• 235000013312 flour Nutrition 0.000 description 1
• 238000002376 fluorescence recovery after photobleaching Methods 0.000 description 1
• 235000013305 food Nutrition 0.000 description 1
• 235000013355 food flavoring agent Nutrition 0.000 description 1
• 230000037406 food intake Effects 0.000 description 1
• 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
• 230000006870 function Effects 0.000 description 1
• 125000000524 functional group Chemical group 0.000 description 1
• 238000003304 gavage Methods 0.000 description 1
• 229960005277 gemcitabine Drugs 0.000 description 1
• SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 1
• 235000001727 glucose Nutrition 0.000 description 1
• 239000008187 granular material Substances 0.000 description 1
• 239000003102 growth factor Substances 0.000 description 1
• 235000010417 guar gum Nutrition 0.000 description 1
• 239000000665 guar gum Substances 0.000 description 1
• 229960002154 guar gum Drugs 0.000 description 1
• 235000015220 hamburgers Nutrition 0.000 description 1
• 230000036541 health Effects 0.000 description 1
• 208000019622 heart disease Diseases 0.000 description 1
• 230000004217 heart function Effects 0.000 description 1
• 208000002672 hepatitis B Diseases 0.000 description 1
• 125000005844 heterocyclyloxy group Chemical group 0.000 description 1
• 229930195733 hydrocarbon Natural products 0.000 description 1
• 150000002430 hydrocarbons Chemical group 0.000 description 1
• 239000008172 hydrogenated vegetable oil Substances 0.000 description 1
• 229920003063 hydroxymethyl cellulose Polymers 0.000 description 1
• 229940031574 hydroxymethyl cellulose Drugs 0.000 description 1
• 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
• 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
• 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
• 239000012216 imaging agent Substances 0.000 description 1
• 125000002962 imidazol-1-yl group Chemical group [*]N1C([H])=NC([H])=C1[H] 0.000 description 1
• 125000002636 imidazolinyl group Chemical group 0.000 description 1
• 230000001771 impaired effect Effects 0.000 description 1
• 238000011503 in vivo imaging Methods 0.000 description 1
• 238000011534 incubation Methods 0.000 description 1
• 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 description 1
• 125000003406 indolizinyl group Chemical group C=1(C=CN2C=CC=CC12)* 0.000 description 1
• 208000015181 infectious disease Diseases 0.000 description 1
• 208000027866 inflammatory disease Diseases 0.000 description 1
• 230000002757 inflammatory effect Effects 0.000 description 1
• 238000001802 infusion Methods 0.000 description 1
• 238000002347 injection Methods 0.000 description 1
• 239000007924 injection Substances 0.000 description 1
• 150000007529 inorganic bases Chemical class 0.000 description 1
• 238000001990 intravenous administration Methods 0.000 description 1
• 238000011835 investigation Methods 0.000 description 1
• 239000011630 iodine Substances 0.000 description 1
• 229910052740 iodine Inorganic materials 0.000 description 1
• 125000004491 isohexyl group Chemical group C(CCC(C)C)* 0.000 description 1
• 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 1
• 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
• 125000005956 isoquinolyl group Chemical group 0.000 description 1
• 125000001786 isothiazolyl group Chemical group 0.000 description 1
• NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
• 238000002372 labelling Methods 0.000 description 1
• 229960001021 lactose monohydrate Drugs 0.000 description 1
• 230000000670 limiting effect Effects 0.000 description 1
• 239000007788 liquid Substances 0.000 description 1
• 229910052744 lithium Inorganic materials 0.000 description 1
• 208000014018 liver neoplasm Diseases 0.000 description 1
• 238000004020 luminiscence type Methods 0.000 description 1
• 229940124302 mTOR inhibitor Drugs 0.000 description 1
• 208000002780 macular degeneration Diseases 0.000 description 1
• 239000011777 magnesium Substances 0.000 description 1
• 230000036210 malignancy Effects 0.000 description 1
• 239000003628 mammalian target of rapamycin inhibitor Substances 0.000 description 1
• 239000011565 manganese chloride Substances 0.000 description 1
• 235000002867 manganese chloride Nutrition 0.000 description 1
• 239000000463 material Substances 0.000 description 1
• 238000013178 mathematical model Methods 0.000 description 1
• 231100000682 maximum tolerated dose Toxicity 0.000 description 1
• 235000012054 meals Nutrition 0.000 description 1
• 229960003194 meglumine Drugs 0.000 description 1
• 238000002844 melting Methods 0.000 description 1
• 230000008018 melting Effects 0.000 description 1
• 229940041616 menthol Drugs 0.000 description 1
• 230000002503 metabolic effect Effects 0.000 description 1
• 229910052751 metal Inorganic materials 0.000 description 1
• 239000002184 metal Substances 0.000 description 1
• 206010061289 metastatic neoplasm Diseases 0.000 description 1
• 229940098779 methanesulfonic acid Drugs 0.000 description 1
• 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 description 1
• 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
• 229960002216 methylparaben Drugs 0.000 description 1
• 125000002816 methylsulfanyl group Chemical group [H]C([H])([H])S[*] 0.000 description 1
• 239000003094 microcapsule Substances 0.000 description 1
• ZYZCGGRZINLQBL-GWRQVWKTSA-N microcystin-LR Chemical compound C([C@H](OC)[C@@H](C)\C=C(/C)\C=C\[C@H]1[C@@H](C(=O)N[C@H](CCC(=O)N(C)C(=C)C(=O)N[C@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]([C@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1)C(O)=O)C(O)=O)C)C1=CC=CC=C1 ZYZCGGRZINLQBL-GWRQVWKTSA-N 0.000 description 1
• DIDLWIPCWUSYPF-UHFFFAOYSA-N microcystin-LR Natural products COC(Cc1ccccc1)C(C)C=C(/C)C=CC2NC(=O)C(NC(CCCNC(=N)N)C(=O)O)NC(=O)C(C)C(NC(=O)C(NC(CC(C)C)C(=O)O)NC(=O)C(C)NC(=O)C(=C)N(C)C(=O)CCC(NC(=O)C2C)C(=O)O)C(=O)O DIDLWIPCWUSYPF-UHFFFAOYSA-N 0.000 description 1
• 238000002156 mixing Methods 0.000 description 1
• 210000001616 monocyte Anatomy 0.000 description 1
• 125000006203 morpholinoethyl group Chemical group [H]C([H])(*)C([H])([H])N1C([H])([H])C([H])([H])OC([H])([H])C1([H])[H] 0.000 description 1
• 125000001064 morpholinomethyl group Chemical group [H]C([H])(*)N1C([H])([H])C([H])([H])OC([H])([H])C1([H])[H] 0.000 description 1
• 208000010125 myocardial infarction Diseases 0.000 description 1
• DXASQZJWWGZNSF-UHFFFAOYSA-N n,n-dimethylmethanamine;sulfur trioxide Chemical group CN(C)C.O=S(=O)=O DXASQZJWWGZNSF-UHFFFAOYSA-N 0.000 description 1
• 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
• GZVYFKDVVRDWRO-UHFFFAOYSA-N n-methyl-8-oxo-9-phenyl-2-pyridin-3-yl-7h-purine-6-carboxamide Chemical compound O=C1NC=2C(C(=O)NC)=NC(C=3C=NC=CC=3)=NC=2N1C1=CC=CC=C1 GZVYFKDVVRDWRO-UHFFFAOYSA-N 0.000 description 1
• 125000004593 naphthyridinyl group Chemical group N1=C(C=CC2=CC=CN=C12)* 0.000 description 1
• 230000027405 negative regulation of phosphorylation Effects 0.000 description 1
• 230000001613 neoplastic effect Effects 0.000 description 1
• 210000000653 nervous system Anatomy 0.000 description 1
• 201000011519 neuroendocrine tumor Diseases 0.000 description 1
• 210000000440 neutrophil Anatomy 0.000 description 1
• 238000010606 normalization Methods 0.000 description 1
• 238000011580 nude mouse model Methods 0.000 description 1
• 235000020824 obesity Nutrition 0.000 description 1
• QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
• OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
• 231100000590 oncogenic Toxicity 0.000 description 1
• 230000002246 oncogenic effect Effects 0.000 description 1
• 230000003287 optical effect Effects 0.000 description 1
• 235000015205 orange juice Nutrition 0.000 description 1
• 235000005985 organic acids Nutrition 0.000 description 1
• 150000007530 organic bases Chemical class 0.000 description 1
• 230000002018 overexpression Effects 0.000 description 1
• 125000001715 oxadiazolyl group Chemical group 0.000 description 1
• AHHWIHXENZJRFG-UHFFFAOYSA-N oxetane Chemical compound C1COC1 AHHWIHXENZJRFG-UHFFFAOYSA-N 0.000 description 1
• 229960001592 paclitaxel Drugs 0.000 description 1
• 229940055726 pantothenic acid Drugs 0.000 description 1
• 235000019161 pantothenic acid Nutrition 0.000 description 1
• 239000011713 pantothenic acid Substances 0.000 description 1
• 239000003182 parenteral nutrition solution Substances 0.000 description 1
• KRRCLLKQQSCVRR-RYVSBMNDSA-N pentyl (2s,3r,4s,5r)-2-(4-amino-5-fluoro-2-oxopyrimidin-1-yl)-3,4-dihydroxy-5-methyloxolane-2-carboxylate Chemical compound C1=C(F)C(N)=NC(=O)N1[C@]1(C(=O)OCCCCC)O[C@H](C)[C@@H](O)[C@H]1O KRRCLLKQQSCVRR-RYVSBMNDSA-N 0.000 description 1
• 235000011197 perejil Nutrition 0.000 description 1
• 230000002688 persistence Effects 0.000 description 1
• 239000008177 pharmaceutical agent Substances 0.000 description 1
• WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical compound OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 1
• 229940043441 phosphoinositide 3-kinase inhibitor Drugs 0.000 description 1
• 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
• 230000026731 phosphorylation Effects 0.000 description 1
• 238000006366 phosphorylation reaction Methods 0.000 description 1
• 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 description 1
• IBBMAWULFFBRKK-UHFFFAOYSA-N picolinamide Chemical compound NC(=O)C1=CC=CC=N1 IBBMAWULFFBRKK-UHFFFAOYSA-N 0.000 description 1
• 239000006187 pill Substances 0.000 description 1
• DNUTZBZXLPWRJG-UHFFFAOYSA-M piperidine-1-carboxylate Chemical compound [O-]C(=O)N1CCCCC1 DNUTZBZXLPWRJG-UHFFFAOYSA-M 0.000 description 1
• 150000003053 piperidines Chemical class 0.000 description 1
• 230000036470 plasma concentration Effects 0.000 description 1
• 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
• 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
• 229920002223 polystyrene Polymers 0.000 description 1
• 229920006316 polyvinylpyrrolidine Polymers 0.000 description 1
• 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
• 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
• 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
• 229920001592 potato starch Polymers 0.000 description 1
• 238000009597 pregnancy test Methods 0.000 description 1
• 239000003755 preservative agent Substances 0.000 description 1
• 230000002335 preservative effect Effects 0.000 description 1
• MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
• 229960004919 procaine Drugs 0.000 description 1
• 239000000047 product Substances 0.000 description 1
• 238000004393 prognosis Methods 0.000 description 1
• 230000000750 progressive effect Effects 0.000 description 1
• 230000002035 prolonged effect Effects 0.000 description 1
• XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 1
• 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
• 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
• 229960003415 propylparaben Drugs 0.000 description 1
• 239000003223 protective agent Substances 0.000 description 1
• 238000000159 protein binding assay Methods 0.000 description 1
• 239000003197 protein kinase B inhibitor Substances 0.000 description 1
• 229940096913 pseudoisocytidine Drugs 0.000 description 1
• 125000001042 pteridinyl group Chemical group N1=C(N=CC2=NC=CN=C12)* 0.000 description 1
• 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
• 150000003217 pyrazoles Chemical class 0.000 description 1
• 125000003072 pyrazolidinyl group Chemical group 0.000 description 1
• 125000002755 pyrazolinyl group Chemical group 0.000 description 1
• ILVXOBCQQYKLDS-UHFFFAOYSA-N pyridine N-oxide Chemical compound [O-][N+]1=CC=CC=C1 ILVXOBCQQYKLDS-UHFFFAOYSA-N 0.000 description 1
• 125000004528 pyrimidin-5-yl group Chemical group N1=CN=CC(=C1)* 0.000 description 1
• HKSQZEGSMBFHGC-UHFFFAOYSA-N pyrimidine-4-carboxamide Chemical compound NC(=O)C1=CC=NC=N1 HKSQZEGSMBFHGC-UHFFFAOYSA-N 0.000 description 1
• 125000006085 pyrrolopyridyl group Chemical group 0.000 description 1
• 230000008707 rearrangement Effects 0.000 description 1
• 230000022983 regulation of cell cycle Effects 0.000 description 1
• 230000016515 regulation of signal transduction Effects 0.000 description 1
• 230000001105 regulatory effect Effects 0.000 description 1
• 230000001850 reproductive effect Effects 0.000 description 1
• 238000002271 resection Methods 0.000 description 1
• 230000000284 resting effect Effects 0.000 description 1
• 230000002441 reversible effect Effects 0.000 description 1
• 238000005070 sampling Methods 0.000 description 1
• 239000000565 sealant Substances 0.000 description 1
• 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
• RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
• 235000012239 silicon dioxide Nutrition 0.000 description 1
• 239000011734 sodium Substances 0.000 description 1
• 229910052708 sodium Inorganic materials 0.000 description 1
• WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
• 235000010234 sodium benzoate Nutrition 0.000 description 1
• 239000004299 sodium benzoate Substances 0.000 description 1
• 229960003885 sodium benzoate Drugs 0.000 description 1
• 229940001607 sodium bisulfite Drugs 0.000 description 1
• 239000001509 sodium citrate Substances 0.000 description 1
• NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
• 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
• 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
• 235000010268 sodium methyl p-hydroxybenzoate Nutrition 0.000 description 1
• 239000008279 sol Substances 0.000 description 1
• 239000007944 soluble tablet Substances 0.000 description 1
• 239000000600 sorbitol Substances 0.000 description 1
• 235000010356 sorbitol Nutrition 0.000 description 1
• 241000894007 species Species 0.000 description 1
• 239000003381 stabilizer Substances 0.000 description 1
• 239000007858 starting material Substances 0.000 description 1
• 239000008117 stearic acid Substances 0.000 description 1
• 238000010254 subcutaneous injection Methods 0.000 description 1
• 239000007929 subcutaneous injection Substances 0.000 description 1
• 239000013589 supplement Substances 0.000 description 1
• 239000000375 suspending agent Substances 0.000 description 1
• 238000003786 synthesis reaction Methods 0.000 description 1
• 238000010189 synthetic method Methods 0.000 description 1
• 239000006188 syrup Substances 0.000 description 1
• 235000020357 syrup Nutrition 0.000 description 1
• 235000002906 tartaric acid Nutrition 0.000 description 1
• 239000011975 tartaric acid Substances 0.000 description 1
• 238000003419 tautomerization reaction Methods 0.000 description 1
• RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
• 125000005944 tetrahydroimidazopyridyl group Chemical group 0.000 description 1
• 125000001712 tetrahydronaphthyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 description 1
• 125000003507 tetrahydrothiofenyl group Chemical group 0.000 description 1
• 125000001113 thiadiazolyl group Chemical group 0.000 description 1
• 125000004927 thianaphthalenyl group Chemical group S1C(C=CC2=CC=CC=C12)* 0.000 description 1
• 125000004305 thiazinyl group Chemical group S1NC(=CC=C1)* 0.000 description 1
• 125000001984 thiazolidinyl group Chemical group 0.000 description 1
• 125000002769 thiazolinyl group Chemical group 0.000 description 1
• 125000004568 thiomorpholinyl group Chemical group 0.000 description 1
• 238000011200 topical administration Methods 0.000 description 1
• 230000009466 transformation Effects 0.000 description 1
• 125000004306 triazinyl group Chemical group 0.000 description 1
• 235000013337 tricalcium citrate Nutrition 0.000 description 1
• LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
• 229910052722 tritium Inorganic materials 0.000 description 1
• 239000000107 tumor biomarker Substances 0.000 description 1
• 210000004881 tumor cell Anatomy 0.000 description 1
• 229940121358 tyrosine kinase inhibitor Drugs 0.000 description 1
• 239000005483 tyrosine kinase inhibitor Substances 0.000 description 1
• 150000004917 tyrosine kinase inhibitor derivatives Chemical class 0.000 description 1
• OOLLAFOLCSJHRE-ZHAKMVSLSA-N ulipristal acetate Chemical compound C1=CC(N(C)C)=CC=C1[C@@H]1C2=C3CCC(=O)C=C3CC[C@H]2[C@H](CC[C@]2(OC(C)=O)C(C)=O)[C@]2(C)C1 OOLLAFOLCSJHRE-ZHAKMVSLSA-N 0.000 description 1
• 125000004417 unsaturated alkyl group Chemical group 0.000 description 1
• 230000004218 vascular function Effects 0.000 description 1
• 230000002861 ventricular Effects 0.000 description 1
• 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
• 238000005406 washing Methods 0.000 description 1
• 238000005550 wet granulation Methods 0.000 description 1
• 239000003871 white petrolatum Substances 0.000 description 1
• 239000002023 wood Substances 0.000 description 1
• RPQZTTQVRYEKCR-WCTZXXKLSA-N zebularine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)N=CC=C1 RPQZTTQVRYEKCR-WCTZXXKLSA-N 0.000 description 1
• 229910052725 zinc Inorganic materials 0.000 description 1
• 239000011701 zinc Substances 0.000 description 1